Measurement, diagnosis, treatment and management of metabolic syndrome

By collecting and monitoring patient information through electronic devices, connecting healthcare professionals, and providing medications and supplies, the problems of adherence and treatment interruption in the management of metabolic syndrome have been solved, achieving effective management of metabolic syndrome and ensuring the continuity and safety of treatment plans.

CN118922890APending Publication Date: 2024-11-08费尔南多·加西亚·萨达
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202380029371.X
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Priority Date
2022-02-24
Filing Date
2023-02-23
Publication Date
2024-11-08

AI Technical Summary

Technical Problem

In the current technology, the prevention and management of metabolic syndrome lack effective monitoring and treatment programs, patients have difficulty maintaining adherence, and the involvement of healthcare professionals is insufficient, leading to treatment interruption or abandonment, which affects health outcomes.

Method used

Collect patient information through electronic devices, connect healthcare professionals, provide medications and supplies, measure and record parameters using interactive user interfaces, monitor and adjust treatment plans in real time, and ensure continuous communication between patients and professionals.

Benefits of technology

It has enabled effective management of metabolic syndrome, improved treatment adherence, ensured the safe and continuous supply of pharmaceutical products, reduced treatment interruptions, and enhanced the monitoring and adjustment capabilities of healthcare professionals.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118922890A_ABST
    Figure CN118922890A_ABST
Patent Text Reader

Abstract

The present invention relates to a method for measuring, diagnosing, treating and managing metabolic syndrome using an electronic device, comprising administering to a patient in need thereof a medicament for treating metabolic syndrome and a system for monitoring a medicament product, in order to prevent or reduce the risk of metabolic syndrome and related conditions, characterized in that the method comprises: providing an electronic device for measuring, diagnosing, treating and managing metabolic syndrome; the method comprises: collecting and storing patient identity information and / or body metric information in a database for incorporation into a medical record; the patient is associated with health care professionals for medical record consultation and registration; provided are pharmaceutical compositions, articles or support devices having pharmaceutical products useful for the prevention, alleviation or management of metabolic syndrome and / or related conditions; connecting one or more devices for measuring clinical parameters and / or anthropometric indicators using an interactive user interface; measuring, recording and storing the collected clinical parameters and / or human body measurement indexes in a database; monitoring, by a health care professional, clinical parameters and / or anthropometric data of the patient; and adjusting or maintaining treatment adaptation.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to a useful method for measuring, diagnosing, treating and managing metabolic syndrome, including administering pharmaceutical products by means of telemedicine to prevent metabolic syndrome and related conditions or reduce their risk, and dispensing pharmaceutical products and supplies by using a user interface that allows communication with measurement devices associated with a set of basic elements to meet a clear purpose between a physician and / or patient. Background Art

[0002] Metabolic syndrome is a group of risk factors that occurs when a person has at least three of the following parameters: a waist circumference of more than 40 inches for men and more than 35 inches for women; triglycerides above 150 milligrams per deciliter of blood (mg / dL); high-density lipoprotein (HDL) cholesterol below 40 mg / dL for men or less than 50 mg / dL for women; fasting blood sugar as high as 100 mg / dL or higher; systolic blood pressure of 130 mmHg or higher and / or diastolic blood pressure of 85 mmHg or higher, leading to an increased risk of health problems such as cardiovascular disease, diabetes, blood clots, fatty liver disease, etc.

[0003] The presence of metabolic syndrome may be caused by physical inactivity, overweight, obesity or genetic conditions, and lack of treatment or control can lead to a worsening of the patient's physical condition and negatively affect their physical performance in daily activities.

[0004] In particular, overweight and obesity are defined as abnormal or excessive accumulation of fat, which can be harmful to health. Currently, there are more than 1.9 billion people over the age of 18 who are overweight, of which 650 million have some degree of obesity, and more than 380 million people under the age of 18 who are overweight or obese, which is why the World Health Organization has classified it as a global epidemic.

[0005] According to the CDC (Centers for Disease Control and Prevention), body mass index (BMI) is a person's weight in kilograms divided by the square of their height in meters. A high BMI may indicate a high level of body fat.

[0006] In this regard, the CDC proposes the following BMI ranges to identify overweight and obesity:

[0007] -BMI is less than 18.5, which is considered underweight.

[0008] -BMI is 18.5 to <25, which is a healthy weight range.

[0009] -BMI is 25.0 to <30, which is considered overweight.

[0010] -A BMI of 30.0 or higher is considered obese.

[0011] Furthermore, based on BMI, obesity is subdivided into 3 categories:

[0012] - Category 1: BMI 30 to <35.

[0013] - Category 2: BMI 35 to <40

[0014] - Category 3: BMI of 40 or higher. "Severe" obesity.

[0015] Compared to people with a healthy weight, overweight people are at greater risk for a variety of serious diseases and health conditions, including the following: high blood pressure (hypertension), high LDL cholesterol, low HDL cholesterol, or high triglyceride levels (dyslipidemia), type 2 diabetes, coronary heart disease, stroke, gallbladder disease, osteoarthritis (the breakdown of cartilage and bone in joints), sleep apnea and breathing problems, several types of cancer, poor quality of life, mental illness (such as clinical depression, anxiety and other psychiatric disorders), bodily pain, and difficulty with physical function, among others.

[0016] It can be seen that obesity and being overweight are the main risk factors for developing metabolic syndrome; however, it also corresponds to a factor that is easily detectable and can be prevented or controlled at any stage.

[0017] Visits to healthcare professionals for metabolic syndrome and related conditions are complicated because they are often done on recommendation; or not at all with such healthcare professionals, choosing to self-medicate or use therapies or exercise devices that promise to reduce weight or improve the patient's health. In addition, patients do not have the time / inclination to visit a physician, physicians do not have the time to adequately care for the patient; and patients do not have the time / inclination to receive treatment, nor do providers have the inventory to provide treatment; leading patients to suspend or abandon treatment.

[0018] There are a variety of methods available for weight management or weight loss; however, patients often resort to diets, exercise routines, or treatments without proper planning or help from a skilled health care professional, resulting in patient suffering, excessive weight gain, or damage to the patient's health once the diet is ended, which may lead to death.

[0019] In cases where dietary supplements or pharmaceutical products are used to treat overweight and obesity, it is critical that health care professionals be included to monitor and participate throughout the treatment process to avoid compromising the patient’s health.

[0020] Difficulty maintaining preventive treatment or control of overweight and obesity and other factors of metabolic syndrome can compromise the patient's health and, therefore, requires a monitoring system during the administration of drug products with continuous access to health care professionals and a classification system for drug products or multiple drug products that meets several objectives: to ensure the quality and safety of the supply of drug products, supplements, supplies, or devices; to provide continuity and motivation to maintain treatment; and to monitor parameters in real time with the help of technology to enable health care professionals to understand the progress of treatment to assess whether it is necessary to modify the treatment regimen or maintain the treatment regimen.

[0021] Purpose of the Invention

[0022] The object of the present invention is to provide a useful method for measuring, diagnosing, treating and managing metabolic syndrome using electronic devices, including administering pharmaceutical products to patients in need thereof to prevent or reduce the risk of metabolic syndrome and related conditions, thereby allowing the appropriate treatment to be dispensed, and to supply healthcare professionals with the pharmaceutical products, supplies and equipment needed for real-time monitoring.

[0023] As a specific goal, the present invention provides different methods to promote compliance with treatment, followed by continuous recommendations on routine, diet, medical appointment cycles, exercise and other activities, which allows strengthening the treatment and its monitoring by health care professionals.

[0024] Another specific objective of the present invention is to maintain: constant connectivity between the patient and the health care professional, avoiding interruptions in data communications between the two parties; constant connectivity between the patient and the provider of pharmaceutical products, supplies or required equipment, avoiding abandonment of treatment due to lack of treatment, and even notifying and reminding the patient before any treatment is completed; and connectivity between the patient and the measurement equipment, avoiding the need to transcribe data or possible errors in transcription. Summary of the invention

[0025] The present invention relates to a useful management method for diagnosing, measuring and treating metabolic syndrome using an electronic device, comprising administering a pharmaceutical product to a patient in need thereof to prevent metabolic syndrome and related conditions or reduce their risk, characterized in that the method comprises:

[0026] (a) Collect and store patient identification information and / or physical measurement information in a database for incorporation into medical records.

[0027] (b) Connect patients with healthcare professionals specializing in metabolic syndrome and related conditions to assess their health status.

[0028] (c) The patient's health condition is indicated and recorded in the medical record.

[0029] (d) explaining to the patient the indications for the treatment of metabolic syndrome and / or related conditions or for the prevention of metabolic syndrome and / or related conditions.

[0030] (e) providing patients in need with drugs for preventing, alleviating or controlling metabolic syndrome and / or

[0031] or pharmaceutical compositions useful as pharmaceutical products for the treatment of diseases or conditions related thereto.

[0032] (f) provide supplies or support equipment for the prevention, alleviation or management of metabolic syndrome and / or related conditions to patients in need thereof.

[0033] (g) using an interactive user interface to connect one or more devices for measuring clinical parameters and / or anthropometric measures.

[0034] (h) measuring, recording and storing in a database the collected clinical parameters and / or anthropometric measures.

[0035] (i) Data on clinical parameters and / or anthropometric measures of patients monitored by healthcare professionals in the field of metabolic syndrome and related conditions to assess their health status.

[0036] (j) adjusting or maintaining the indication for treating the metabolic syndrome and / or related conditions or for preventing the metabolic syndrome and / or related conditions in the patient.

[0037] (k) Optionally, assistance is provided to the patient by a health care professional during prescribed time periods or upon request by the patient or the health care professional. BRIEF DESCRIPTION OF THE DRAWINGS

[0038] The following is a description of an exemplary embodiment of the present invention consistent with the specification, and the "exemplary embodiment" includes specific aspects, structures or features, which can be integrated by other exemplary embodiments described or not described. Therefore, the exemplary embodiments described below are not restrictive; therefore, different software or hardware implementations, interfaces, execution methods, storage or reading, instructions, etc. can be implemented.

[0039] Figure 1 is a graphical representation of a useful method for measuring, diagnosing, treating and managing metabolic syndrome using an electronic device, comprising administering a pharmaceutical product to a patient (100) in need thereof to prevent or reduce the risk of metabolic syndrome and related conditions, characterized in that the method comprises:

[0040] collecting (101) and storing patient identification information (102a) and / or physical measurement information (102c) in a database (103) for incorporation into a medical record (102b);

[0041] The patient (100) is connected (111) to a health care professional (110) specializing in metabolic syndrome and related conditions to assess his / her health status; his / her health status is indicated to the patient (111b) and recorded in the medical record (102b); and the patient is informed (111c) of the indications for treating the metabolic syndrome and / or related conditions he / she suffers from or preventing the metabolic syndrome and / or related conditions.

[0042] A pharmaceutical composition (130) having a drug product useful for preventing, alleviating or controlling metabolic syndrome and / or related disorders is provided (121a) to a patient (100) in need thereof via a pharmacy (120).

[0043] c(120), providing (121b) supplies (140a) or measuring devices (140) for preventing, alleviating or controlling metabolic syndrome and / or related conditions to a patient (100) in need thereof.

[0044] One or more devices (140b) for measuring clinical parameters and / or anthropometric indices are connected (151) using an interactive user interface (150).

[0045] The collected clinical parameters and / or anthropometric measures (102c) are measured (141), recorded (142) and stored (143) in a database (103).

[0046] Data on clinical parameters and / or anthropometric measures (102c) of a patient (100) is monitored (112) by a healthcare professional (110) in the field of metabolic syndrome and related conditions to assess their health status.

[0047] Adjust or maintain the indication for treating the metabolic syndrome and / or related conditions in the patient or for preventing the metabolic syndrome and / or related conditions (113).

[0048] Optionally, assistance (114) is provided to the patient (100) by the health care professional (110) within a specified time period or upon request by the patient or the health care professional.

[0049] Figure 2 An embodiment of a useful method for measuring, diagnosing, treating and managing metabolic syndrome using an electronic device is shown, comprising administering a pharmaceutical product to a patient in need thereof to prevent metabolic syndrome and related conditions or reduce their risk, characterized in that the method comprises:

[0050] Based on the patient's identity information (102a) and body measurement information (102c) previously stored in a database (103) and / or the patient's medical records (102b), a pharmaceutical composition (130) having a pharmaceutical product useful for preventing, alleviating or controlling metabolic syndrome and / or related conditions is provided (121a) to the patient (100).

[0051] A health care professional (110) in the field of metabolic syndrome and related conditions monitors (112) clinical parameters and / or anthropometric data of a patient to assess the patient's health status through an interactive user interface (150) connected to one or more devices for measuring clinical parameters and / or anthropometric indicators, wherein the interactive user interface (150) records (142) and stores (143) the clinical parameters and / or anthropometric indicators.

[0052] Figure 3 Various embodiments are shown of useful methods for measuring, diagnosing, treating, and managing metabolic syndrome using electronic devices, including administering a pharmaceutical product to a patient in need thereof to prevent or reduce the risk of metabolic syndrome and related conditions.

[0053] In one embodiment, a method for measuring, diagnosing, treating and managing metabolic syndrome using an electronic device comprises administering a pharmaceutical product to a patient receiving treatment for prevention, alleviation or management of metabolic syndrome and / or related conditions, characterized in that the method comprises:

[0054] collecting (101) and storing in a database (103) patient identification information (102a) and / or physical measurement information, clinical parameters and / or anthropometric indicators (102c) for incorporation into a medical record (102b);

[0055] Based on the patient identity information (102a) and the patient clinical parameters and / or anthropometric index information (102c) and / or the patient's medical records (102b) previously stored in the database, a pharmaceutical composition (130) having a pharmaceutical product useful for preventing, alleviating or controlling metabolic syndrome and / or related conditions is provided (121a) to a patient (100) in need thereof through a pharmacy (120).

[0056] Clinical parameters and / or anthropometric measures (102c) collected from the patient during treatment are measured (141), recorded (142) and stored (143) in a database (103).

[0057] Data on clinical parameters and / or anthropometric measures (102c) of a patient (100) are monitored (112) by a healthcare professional (110) in the field of metabolic syndrome and related conditions to assess their health status; to adjust or maintain indications (113) for treating metabolic syndrome and / or related conditions suffered by the patient or for preventing metabolic syndrome and / or related conditions.

[0058] In one embodiment, a useful method for measuring, diagnosing, treating and managing metabolic syndrome using an electronic device comprises administering a pharmaceutical product to a patient in need thereof to prevent metabolic syndrome and related conditions or reduce their risk, characterized in that the method comprises:

[0059] connecting patients (100) to health care professionals (110) specialized in metabolic syndrome and related conditions (111) to assess their health status;

[0060] Indicate the patient's health condition (111b) and record it in the medical record (102b);

[0061] Explain to the patient (111c) the indications for treating the metabolic syndrome and / or related disorders or for preventing the metabolic syndrome and / or related disorders.

[0062] A pharmaceutical composition (130) having a drug product useful for preventing, alleviating or controlling metabolic syndrome and / or related disorders is provided (121a) to a patient (100) in need thereof via a pharmacy (120).

[0063] Physical measurements, clinical parameters and / or anthropometric indicators (102c) collected from the patient during treatment are recorded (142) and stored (143) in a database (103).

[0064] During treatment, the patient's clinical parameters and / or anthropometric measures are recorded and stored in a database.

[0065] Data on clinical parameters and / or anthropometric measures (102c) of a patient (100) is monitored (112) by a healthcare professional (110) in the field of metabolic syndrome and related conditions to assess their health status.

[0066] Adjust or maintain the indication for treating the metabolic syndrome and / or related conditions in the patient or for preventing the metabolic syndrome and / or related conditions (113).

[0067] In another embodiment, a useful method for measuring, diagnosing, treating and managing metabolic syndrome using an electronic device comprises administering a pharmaceutical product to a patient in need thereof to prevent metabolic syndrome and related conditions or reduce their risk, characterized in that the method comprises:

[0068] A pharmaceutical composition (130) having a drug product useful for preventing, alleviating or managing metabolic syndrome and / or related conditions is provided (121a) to a patient (100) in need thereof via a pharmacy (120).

[0069] Supplies (140a) or support equipment (140b) for preventing, alleviating or controlling metabolic syndrome and / or related conditions are provided (121b) to patients (100) in need thereof through a pharmacy (120).

[0070] One or more devices (140b) for measuring clinical parameters and / or anthropometric indices are connected (151) using an interactive user interface (150).

[0071] The collected clinical parameters and / or anthropometric measures (102c) are measured (141), recorded (142) and stored (143) in a database (103).

[0072] monitoring (112) data of clinical parameters and / or anthropometric measures (102c) of a patient (100) by a healthcare professional (110) in metabolic syndrome and related conditions to assess their health status;

[0073] Adjust or maintain the indication for treating the metabolic syndrome and / or related conditions in the patient or for preventing the metabolic syndrome and / or related conditions (113).

[0074] In another embodiment, a useful method for measuring, diagnosing, treating and managing metabolic syndrome using an electronic device comprises administering a pharmaceutical product to a patient in need thereof to prevent metabolic syndrome and related conditions or reduce their risk, characterized in that the method comprises:

[0075] A pharmaceutical composition (130) having a drug product useful for preventing, alleviating or controlling metabolic syndrome and / or related disorders is provided (121a) to a patient (100) in need thereof via a pharmacy (120).

[0076] One or more devices (140b) for measuring clinical parameters and / or anthropometric indices are connected (151) using an interactive user interface (150).

[0077] The collected clinical parameters and / or anthropometric measures (102c) are measured (141), recorded (142) and stored (143) in a database (103).

[0078] Data on clinical parameters and / or anthropometric measures (102c) of a patient (100) is monitored (112) by a healthcare professional (110) in the field of metabolic syndrome and related conditions to assess their health status.

[0079] Adjust or maintain the indication for treating the metabolic syndrome and / or related conditions in the patient or for preventing the metabolic syndrome and / or related conditions (113).

[0080] Figure 4 An embodiment of a system for monitoring at least one clinical parameter and / or anthropometric index of a patient (100) in need thereof to prevent metabolic syndrome and related conditions or reduce their risk is shown. The system includes a device and interface (160a) for entering patient identification information and / or anthropometric information into a database; a device and interface (160b) for collecting and storing patient identification information and / or anthropometric information in a database for incorporation into a medical record; an access device (170) for communication between the patient and a health care professional in the field of metabolic syndrome and related conditions to assess their health status; a device (170a) for indicating to the patient their health status and recording it in the medical record; a device (170b) for explaining to the patient the indications for treating the metabolic syndrome and / or related conditions they suffer from or for preventing metabolic syndrome and / or related conditions; a device (120) for providing (121a) to a patient in need thereof a pharmaceutical composition having a pharmaceutical product useful for preventing, alleviating or controlling metabolic syndrome and / or related conditions; a device (121b) for providing to a patient in need thereof a pharmaceutical composition (120) having a pharmaceutical product useful for preventing, alleviating or controlling metabolic syndrome and / or related conditions; and a device (121c) for providing to a patient in need thereof a pharmaceutical composition (120) having a pharmaceutical product useful for preventing, alleviating or controlling metabolic syndrome and / or related conditions. b) a device for supplies or support equipment for preventing, alleviating or controlling metabolic syndrome and / or related conditions; a device for connecting one or more devices for measuring clinical parameters and / or anthropometric indices using an interactive user interface (152); a database (103) for recording and storing collected clinical parameters and / or anthropometric indices; a device for monitoring (112) a patient's clinical parameter and / or anthropometric data by a health care professional in the field of metabolic syndrome and related conditions to assess their health status; an access device for a health care professional to adjust or maintain an indication (113) for treating the patient's metabolic syndrome and / or related conditions or for preventing metabolic syndrome and / or related conditions; and, optionally, an access device for establishing communication (114) between the patient and the health care professional within a specified time period or upon request of the patient or the health care professional.

[0081] Figure 5 Embodiments of useful methods for measuring, diagnosing, treating and managing metabolic syndrome using electronic devices are shown, including administering a pharmaceutical product to a patient in need thereof to prevent or reduce the risk of metabolic syndrome and related conditions, characterized in that the method comprises:

[0082] A monitoring system (200) for treatment or prevention is provided to patients and health care professionals, the system comprising at least: a device and interface (160a) for inputting patient identification information and / or body measurement information into a database; a device and interface (160b) for collecting and storing patient identification information and / or body measurement information in a database for incorporation into a medical record; an access device (170) for communication between a patient and a health care professional in the field of metabolic syndrome and related conditions to assess their health status; a device (170a) for indicating to a patient their health status and recording it in the medical record; a device (170b) for explaining to a patient the indications for treating the metabolic syndrome and / or related conditions they suffer from or for preventing the metabolic syndrome and / or related conditions; a device (121a) for providing a patient in need thereof with a pharmaceutical composition having a pharmaceutical product useful for preventing, alleviating or controlling the metabolic syndrome and / or related conditions; 0); a device for providing (121b) supplies or support equipment for preventing, alleviating or controlling metabolic syndrome and / or related conditions to a patient in need thereof; a device for connecting one or more devices for measuring clinical parameters and / or anthropometric indices using an interactive user interface (152); a database (103) for recording and storing collected clinical parameters and / or anthropometric indices; a device for monitoring (112) a patient's clinical parameter and / or anthropometric data by a health care professional in the field of metabolic syndrome and related conditions to assess their health status; an access device for a health care professional to adjust or maintain an indication (113) for treating the patient's metabolic syndrome and / or related conditions or for preventing metabolic syndrome and / or related conditions; and, optionally, an access device for establishing communication (114) between the patient and the health care professional within a specified time period or upon request by the patient or the health care professional.

[0083] Based on the patient identification information and body measurement information previously stored in a database or the patient's medical records, a pharmaceutical composition (130) having a drug product useful for preventing, alleviating or controlling metabolic syndrome and / or related conditions is provided to the patient (100).

[0084] A healthcare professional (110) in the field of metabolic syndrome and related conditions monitors clinical parameters and / or anthropometric data of a patient to assess his or her health status using an interactive user interface connected to one or more devices for measuring clinical parameters and / or anthropometric data.

[0085] Figure 6A system for monitoring at least one clinical parameter and / or anthropometric index of a patient in need thereof using an electronic device associated with a device for measuring clinical parameters and / or anthropometric indexes to prevent or reduce the risk of metabolic syndrome and related conditions is shown, characterized in that the system comprises:

[0086] A patient monitoring module is installed in the patient's electronic device (160a).

[0087] at least one device (140) for measuring clinical parameters and / or anthropometric indices, connected to the patient's electronic device (160a);

[0088] Communication means (180) between the patient's electronic device (160a) and the device (140) for measuring clinical parameters and / or anthropometric indices;

[0089] The patient monitoring module is configured to: (i) collect (101) patient identification information (102a) and / or body measurement information (102c); (ii) (141), record (142) and store (143) in a database (103) the collected patient clinical parameters and / or anthropometric indicators (102c); (iii) store the information in the database (103) for incorporation into the medical record (102b); (iv) connect the patient (100) with a health care professional (110) in the field of metabolic syndrome and related conditions (111) to assess the patient's health status, indicate the patient's health status (111b), record it in the medical record (102b), and explain to the patient (111c) the indications for treating the metabolic syndrome and / or related conditions or for preventing the metabolic syndrome and / or related conditions; (v) providing (121a) a pharmaceutical composition (130) having a drug product useful for preventing, alleviating or controlling metabolic syndrome and / or related conditions, and supplies (140a) or supporting equipment (140b) to a patient (100) in need thereof through a pharmacy (120); (vi) establishing a connection (151) with at least one device (140) for measuring clinical parameters and / or anthropometric indices; (vii) measuring (141), recording (142) and storing (143) in a database (103) clinical parameters and / or anthropometric indices (102c); (viii) measuring (141), recording (142) and storing (143) in a database (103) clinical parameters and / or anthropometric indices (102c) obtained from at least one device (140) for measuring clinical parameters and / or anthropometric indices;

[0090] (vii) allowing a healthcare professional (110) specializing in metabolic syndrome and related conditions to access (170) the patient's medical records to assess his or her health status and adjust or maintain treatment indications (113); and optionally, (ix) establishing communications (114) between the patient (100) and the healthcare professional (110) within a specified time period or upon request by the patient or healthcare professional.

[0091] Figure 7 A connection model is shown for connecting a monitoring system for at least one clinical parameter and / or anthropometric index to a patient (100) in need thereof by a health care professional (110) to prevent metabolic syndrome and related conditions or reduce their risk; using an electronic device associated with a device (140) for measuring clinical parameters and / or anthropometric indexes, a pharmaceutical composition (130) having a pharmaceutical product useful for preventing, alleviating or controlling metabolic syndrome and / or related conditions, characterized in that the system includes: a user interface, a communication device and a database.

[0092] A patient, healthcare professional, or authorized third party who accesses the information stored in the interface or database can visualize clinical parameters and / or anthropometric measures along with patient information and records through the interface. The information provided to the patient or authorized third party indicates standard ranges for measurements and indicates if there are any risk factors that need to be addressed; or displays progress made with treatment, allowing monitoring by the patient and healthcare professional or authorized third party to take immediate action to achieve goals set for treatment.

[0093] The device and interface (160a) for entering patient identity information and / or physical measurement information into a database and the device and interface (160b) for collecting and storing patient identity information and / or physical measurement information in a database for incorporation into medical records can be any laptop or desktop computer, electronic tablet, smart display, smart screen, smart phone, video game console, media player device, smart watch, smart bracelet or any device capable of inputting data via written text, sound or some encoding; and having a wired or wireless connection.

[0094] In a non-limiting embodiment, the patient (100) is connected (111) with a health care professional (110) in the field of metabolic syndrome and related conditions for the assessment of their health status through a video call, using an electronic device, with prior identification of the patient and the health care professional. Once the connection is established, the medical office integrates all information from the patient's file or on-site measurements using equipment for measuring clinical parameters and / or anthropometric indicators; thereby providing treatment indications by the physician and his prescription orders to provide a pharmaceutical composition with a drug product useful for preventing, alleviating or controlling metabolic syndrome and / or related conditions.

[0095] Identification of patients and healthcare professionals can be accomplished through a number of implementations, such as a password, identification number, username, or biometric identification (fingerprint, retinal or facial recognition), ID card, and other identification methods.

[0096] To operate, the user interface for patients and health care professionals can be connected to one or more screens, printers, speakers, and / or other devices. The interface can include notifications, links, buttons, tabs, check boxes, bullets, text fields, drop-down boxes, etc., and can provide various outputs such as text, static images, video, audio, and animation in response to user input.

[0097] The connection can be selected from LAN, WLAN, tree or ring topology network, wireless Internet access point system, Ethernet, Internet, radio communication, infrared, fiber optic and 2G, 3G, 4G or 5G data phone.

[0098] Pharmaceutical compositions (130) having drug products useful for preventing, alleviating or controlling metabolic syndrome and / or related conditions include drug products for preventing, alleviating or controlling overweight, obesity, hyperglycemia (type I diabetes or type II diabetes), hypertension, heart disease, dyslipidemia and other related conditions.

[0099] In a preferred embodiment, the pharmaceutical composition (130) having a drug product useful for preventing, alleviating or controlling metabolic syndrome and / or related conditions comprises a drug product for preventing, alleviating or controlling overweight and obesity selected from: chemical uncouplers of oxidative phosphorylation, tyrosine phosphorylation inhibitor AG17, orlistat, L-carnitine, benzphetamine, phendimetrazine, diethylpropion, liraglutide, naltrexone, phentermine, topiramate, glibenclamide, dimethoate, phentermine, phenoxyethanol ... Metformin, acarbose, canagliflozin, dapagliflozin, saxagliptin, dulaglutide, empagliflozin, exenatide, lixisenatide, semaglutide, CBD, sibutramine, hydroxycitric acid, coenzyme q10, chromium picolinate, gamma-linolenic acid, resveratrol, omega-3 fatty acids, antioxidants, vitamins, vitamin B, vitamin C, adrenal extract, pantothenic acid, Curcuma longa longa), Bayberry bark, Myricacerifera, Oryza sativa L.indica, Camellia sinensis, Theobromacacao, Emblica officinalis, Ilex paraguariensis, Cascara sagrada bark, Rhamnus purshiana, Acacianilotica, Persimmon, Blueberry leaf, Grape seed, Cordia salicifolia, Hypericum perforatum, Pueraria thomsonn, Capparis spinosa, Pueraria thomsonn, Elderberry, Sambicus, Citrus aurantium, Coffee beanscanefora, Sygium cumini, Rosemary (Rosmarinusofficinalis), Ginger (Zingiber officinalis), Cassia nomame, Cissus quadrangularis, Phaseolus vulgaris, Licorice Root, Fenugreek, Yohimbe, White willow, Cordyceps sinensis, Ashwaganda, Astragalus, Gingseng, Schisandra, Siberian gingseng, Asian ginseng, Commiphoramukul, Momordica charantia, Garcinia cambogia), Althaea officinalis, Bougainvillea spectabilis, Medicago sativa, Valerian officinalis, Damiana, Sambucusnigra), Capsicum, Allium, calcium myristate, magnesium myristate, tetradecylthioacetic acid (TTA), thyroid hormone or its precursor, thyroid function enhancer, Krebs cycle metabolite, one or more endogenous uncoupling proteins (such as UCP-1, UCP-2, UCP-3, PUMP (plant uncoupling mitochondrial protein) or one or more precursors, one or more agonists or enhancers), leucine, valine, isoleucine, glutamine, proline, tyrosine, conjugated linoleic acid, adrenaline secretion enhancer, fatty acid or ester, beta agonist, glucagon, abutamine, vasopressin, ubiquinone, coenzyme 01, coenzyme Q2, melatonin, estrogen Fatty acid esters (such as oleylestrone), glucomannan, menthol, peppermint essential oil, thyme essential oil, elemental sulfur and policosanol, insulin or insulin analogs, and orally active hypoglycemic agents; acetohexamide, carbutamide, chlorpropamide, glibenclamide, glibornuride, gliclazide, glimepiride, glipizide, tolazamide and tolbutamide. 2R,3R,4R,5S)-1-(2-hydroxyethyl)-2-(hydroxymethyl)piperidin-3,4,5-triol or miglitol) (1S,2S,3R,4S,5S)-5-(1,3-dihydroxypropan-2-ylamino)-1-(hydroxymethyl)-cyclohexane-1,2,3,4-tetraol), (RS)-5-[4-(2-[methyl(pyridin-2-yl)amino]ethoxy)benzyl]thiazolidine-2,4-dione, (RS)-5-(4-[2-(5-ethylpyridin-2-yl)ethoxy]benzyl)thiazolidine-2,4-dione, 5-[(4-[2-([6-(4-methoxyphenoxy)pyrimidin-4-yl]-methylamino)ethoxy]phenyl-)methyl]-1,3-thiazolidine-2,4 -dione, (RS)-5-(4-[(6-hydroxy-2,5,7,8-tetramethylchroman-2-yl)methoxy]benzyl)thiazolidine-2,4-dione; (S)-(+)-2-ethoxy-4-[2-(3-methyl-1-[2-(piperidin-1-yl)phenyl]butylamino)-2-oxyylideneethyl]benzoic acid, 3-phenyl-2-[(4-propan-2-ylcyclohexanecarbonyl)amino]propionic acid, (2S)-2-benzyl-4-[(3aR,7aS)-octahydro-2H-isoindol-2-yl]-4-oxyylidenebutanoic acid, L-ornithine, L-tyrosine, L-tryptophan, L-phenylalanine, conjugated linoleic acid, gamma-linolenic acid, chromium picolinate, glucose tolerance factor, vanadyl sulfate, Gymnema sylvestresylvestre), bromelain, pancreatin, papain, coenzyme Q10, curcumin, barberry, bearberry, silymarin (Teucrium polium), Teucrium polium, choline, inositol, human growth hormone, DHEA (dehydroepiandrosterone), caffeine, xanthenes (such as fucoxanthin), kola nut, plantain, yerba mate ( mate), guarana, ginseng, medium chain triglycerides, hydroxycitric acid (HCA), kelp, lecithin, dihydroxyacetone, pyruvic acid, creatine, iodine, niacin, fucus vesiculosus, white bean extract, glucomannan, chitosan, resveratrol, resveratrol derivatives, vitamin D, hCG, capsaicin, chia, hoodia, apple cider vinegar, coconut oil, bitter orange, vitamin B, fluoxetine, chitosan, chromium picolinate, conjugated linoleic acid (CLA), glucomannan, green tea extract, green coffee extract, guar gum, hoodia, 7-keto-DHEA, DHEA, ephedra, bitter orange, turmeric, ginger, root powder, apple cider vinegar, calcium, hesperidin, apantipan gynostemma), extract linseed oil, orange peel powder, thiamine, ashwagandha extract, coffee extract, L-theanine, choline bitartrate, red mango extract, white kidney bean extract, c. cinephora robusta extract, acetyl-L carnitine, garcinia, cumbusia extract, coconut oil, forskolin extract, black pepper extract, seroxat, citalopram, bupropion, topiramate, ecopipam, naltrexone, peptide YY3-36, leptin, examphetamine, amphetamine, phentermine, mazindolphendimetrazine, bupropion, fenfluramine, dexfenfluramine, pharmaceutically acceptable salts and derivatives thereof, and mixtures thereof.

[0100] In another embodiment, the pharmaceutical composition (130) having a drug product useful for preventing, alleviating or controlling metabolic syndrome and / or related conditions comprises a drug product for preventing, alleviating or controlling hyperglycemia (type I diabetes or type II diabetes) selected from the group consisting of: chemical uncouplers of oxidative phosphorylation, biguanides, imidazolines, α-glucosidase inhibitors, meglitinida, oxadiazolidindiones, thiazolidindiones. iones), insulin sensitizers, sulfonylureas, potassium channel blockers such as nateglinide or BTS-67582, glucagon antagonists, inhibitors DPP-IV (dipeptidyl peptidase-IV), PTPase (protein tyrosine phosphatase) inhibitors, glucokinase activators, enzymes and metabolites involved in regulating gluconeogenesis or glycogenolysis, glucose uptake regulators, GSK-3 (glycogen synthase kinase-3) inhibitors, compounds that alter lipid metabolism such as antihyperlipidemic and hypolipidemic drugs, compounds that reduce food intake, and PPAR agonists;For example: tyrosine phosphorylation inhibitor AG17, tyrosine phosphorylation inhibitor A9, insulin and insulin analogs, tolbutamide, chlorpropamide, tolazamide, glyburide, glipizide, glimepiride, gliclazide or gliburide, metformin, repaglinide or senaglinide / nateglinide, troglitazone, pioglitazone, rosiglitazone, isaglitazone, darglitazone, englitazone, GI 262570, YM-440, MCC-555, JTT-501, AR-H039242, KRP-297, GW-409544, CRE-16336, AR-H, voglibose, emiglitate, miglitol or acarbose, tolbutamide, glibenclamide, glipizide, gliclazide, BTS-67582 or repaglinide, nateglinide, colestiramine, colestipol, clofibrate, gemfibrozil, lovastatin, pravastatin, simvastatin, pharmaceutically acceptable salts and derivatives thereof and mixtures thereof. ;

[0101] In another embodiment, the pharmaceutical composition (130) having a drug product useful for preventing, alleviating or controlling metabolic syndrome and / or related conditions comprises a drug product for preventing, alleviating or controlling hypertension selected from: alprenolol, atenolol, timolol, pindolol, propranolol and metoprolol, ACE (angiotensin converting enzyme) inhibitors such as benazepril, captopril, enalapril, fosinopril, lisinopril, quinapril and ramipril, calcium channel blockers such as nifedipine, felodipine, nicardipine, isradipine, nimodipine, diltiazem and verapamil, and [α]-blockers such as doxazosin, urapidil, prazosin and terazosin, pharmaceutically acceptable salts and derivatives thereof and mixtures thereof.

[0102] Chemical uncouplers of oxidative phosphorylation include, but are not limited to, the following compounds: 4,4-bis-(4-hydroxy-3-nitrophenyl)-pentanoic acid, 4-methoxy-2-nitrophenol, 4-hydroxy-3-nitroacetophenone, 7-hydroxy-4-methyl-8-nitro-chromen-2-one, 3-tert-butyl-5-chloro-N-(2-chloro-4-nitrophenyl)-2-hydroxy-6-methyl-benzamide, N-1-[4-cyano-3-(trifluoromethyl)phenyl]-3,5-bis(trifluoromethyl)benzene Formamide, N-(4-cyanophenyl)benzamide, 2′-chloro-1-hydroxy-4′-nitro-2-naphthoic acid anilide, N-(2-chloro-4-bromophenyl)-5-bromosalicylic acid anilide, N-(2-chloro-4-nitrophenyl)-3-tert-butyl-6-methylsalicylic acid anilide, (3,5-di-tert-butyl-4-hydroxybenzyl)triphenylphosphonium bromide, (3,5-di-tert-butyl-4-hydroxybenzyl)tricyclohexylphosphonium bromide, (3,5-di-tert-butyl-4-hydroxybenzyl)tributylphosphonium bromide Phosphine, (3,5-di-tert-butyl-4-hydroxybenzyl) trioctylphosphine bromide, 2-cyano-3-(3,5-di-tert-butyl-4-hydroxyphenyl)-acrylate, 2-(3,5-di-tert-butyl-4-hydroxy-benzylidene)-malonic acid diethyl ester, 2-amino-S-[(3,5-di-tert-butyl-4-hydroxybenzylidene)-amino]-but-2-enediconitrile, 2-(3,5-di-tert-butyl-4-hydroxy-benzylidene)-indane-1,3-dione, 2-[[2-(4 -chlorophenyl)-1H-indol-3-yl]methylene]malononitrile, 2-(4-chlorophenyl)-indole, N-(2,4,5-trichlorophenyl) salicylanilide, 2,3-dimethyl-5-cyano-7-ethylindole, 4-bromo-2-(4-chlorophenyl)-5-trifluoromethyl-1H-pyrrole-3-carbonitrile, N-(3-cyano-4-phenylthio-phenyl)-3-trifluoromethyl-benzamide, 2,4-dinitrophenol, carbonyl cyanide p-trifluoromethoxy-phenylhydrazone, 2-(5,7-dimethyl-1H-indol-3-ylmethylene)-malononitrile, 2-(5-bromo-1H-indol-3-ylmethylene)-malononitrile, 2-((5-chloro-1H-indol-3-yl)methylene)malononitrile, 2-((5-methyl-1H-indol-3-yl)methylene)malononitrile, 2-((5-methyl-1H-indol-3-yl)methylene)malononitrile, 2-((5-methyl-1H-indol-3-yl)methylene)malononitrile, 2-(2-phenyl-3-indolylmethylene)-malononitrile, 2-(2-chloro-1H-indol-3-ylmethylene)-malononitrile, 2-(5-nitro-1H-indol-3-ylmethylene)-malononitrile, 2-(2-methyl-5-nitro-1H-indol-3-ylmethylene)-malononitrile, 3-bromo-5-tert-butyl Benzamide, 3-tert-butyl-N-(2-chloro-4-nitrophenyl)-6-hydroxy-2-methyl-benzamide, N-(2-chloro-4-nitrophenyl)-2-hydroxy-3-isopropyl-benzamide, N-(2-chloro-4-nitrophenyl)-2-hydroxy-3-isopropyl-6-methyl-benzamide, 3,5-di-tert-butyl-N-(2-chloro-4-nitrophenyl)-2-hydroxy-benzamide, 3-bromo-N-(2-chloro-4-nitrophenyl)-6-hydroxy-5-isopropyl-2-methyl-benzamide, 3-tert-butyl-5-chloro-N-(4-chloro-3-trifluoromethyl-phenyl)-2-hydroxy-6-methyl-benzamide, 3-tert-butyl-5-chloro-N-(4-cyano-3-trifluoromethyl-phenyl)-2-hydroxy-6-methyl-benzamide 2-Hydroxy-biphenyl-3-carboxylic acid (2-chloro-4-nitro-phenyl)-amide, 3-tert-butyl-N-(2-chloro-4-nitro-phenyl)-2-hydroxy-5-methyl-benzamide, N-(2-chloro-4-nitro-phenyl)-2-hydroxy-6-isopropyl-3-methyl-benzamide, N-(3,5-bis-trifluoromethyl-phenyl)-3-tert-butyl-5-chloro-2-hydroxy-6-methyl-benzamide, 3-tert-butyl-5-chloro-N-(2-fluoro-5-trifluoromethyl-phenyl)-2-hydroxy-6-methyl-benzamide, 3-tert-butyl-5-chloro-2-hydroxy-6-methyl-N-(4-nitro-3 -trifluoromethyl-phenyl)-benzamide, 3-tert-butyl-5-chloro-2-hydroxy-6-methyl-N-(4-nitro-2-trifluoromethyl-phenyl)-benzamide, 3-bromo-5-tert-butyl-N-(2-chloro-4-cyano-phenyl)-6-hydroxy-2-methyl-benzamide, 3-bromo-5-tert-butyl-N-(2-chloro-5-trifluoromethyl-phenyl)-6-hydroxy-2-methyl-benzamide, 3-bromo-5-tert-butyl-N-(2,4-dichloro-phenyl)-6-hydroxy-2-methyl-benzamide, 3-bromo-5-tert-butyl-N-(2,4-dichloro-6-nitro-phenyl)-6-hydroxy-2-methyl-benzamide,6-dichloro-4-nitro-phenyl)-6-hydroxy-2-methyl-benzamide, 3-bromo-5-tert-butyl-N-{5-chloro-4-[(4-chloro-phenyl)-cyano-methyl]-2-methyl-phenyl}-6-hydroxy-2-methyl-benzamide, 3-bromo-6-hydroxy-5-isopropyl-2-methyl-N-(4-nitro-2-trifluoromethyl-phenyl)-benzamide, 3-bromo-5-tert-butyl-6-hydroxy-2-methyl-N-(4-nitro-2-trifluoromethyl-phenyl)-benzamide, 3-tert-butyl-2-hydroxy-6-methyl-N-(4-nitro-2-trifluoromethyl-phenyl)-benzamide, 3-bromo-N-(2-bromo-3,5-bis-trifluoromethyl-phenyl)-5-tert-butyl-6 -hydroxy-2-methylbenzamide, N-(2,5-bis-trifluoromethyl-phenyl)-3-bromo-5-tert-butyl-6-hydroxy-2-methyl-benzamide, 3-bromo-5-tert-butyl-N-(2,4-dichloro-6-trifluoromethyl-phenyl)-6-hydroxy-2-methylbenzamide, 3-bromo-5-tert-butyl-6-hydroxy-N-(4-isopropyl-2-trifluoromethyl-phenyl)-2-methyl-benzamide, N-(3,5-bis-trifluoromethyl-phenyl)-3-fluoro-5-trifluoromethyl-benzamide, 3-fluoro-N-(4-nitro-3-trifluoromethyl-phenyl)-5-trifluoromethyl-benzamide, N-(3,5-bis-trifluoromethyl-phenyl)-3-fluoro-4-trifluoromethyl-benzamide, -Fluoro-N-(4-nitro-3-trifluoromethyl-phenyl)-3-trifluoromethyl-benzamide, 3-(3,5-di-tert-butyl-4-hydroxy-phenyl-2-(2,2-dimethyl-propionyl)-acrylonitrile, 2-acetyl-3-(3,5-di-tert-butyl-4-hydroxy-phenyl)-ethyl acrylate, 2-(3,5-dimethyl-4-hydroxy-benzylidene)-malononitrile, 2-(3,5-dimethyl-4-hydroxy-benzylidene)-malononitrile, 2,6-di-tert-butyl-4-nitro-phenol, 2-tert-butyl-4,6-dinitro-phenol, 3-(3,5-di-tert-butyl-4-hydroxy-phenyl)-2-pyridin-2-yl-acrylonitrile, 2-[1-(3,5-di-tert-butyl-4-hydroxy-phenyl) -ethylidene]-malononitrile, 3-(3,5-di-tert-butyl-4-hydroxybenzylidene)-2-(diethylphosphonate)-acrylonitrile, 3-(3,5-di-tert-butyl-4-hydroxy-phenyl)-2-(4-nitro-phenyl)-acrylonitrile, 3-(3,5-di-tert-butyl-4-hydroxy-phenyl)-2-pyridin-4-yl-acrylonitrile, 2-(3,5-bis-trifluoromethyl-phenyl)-3-(3,5-di-tert-butyl-4-hydroxy-phenyl)-acrylonitrile, 3-(3,5-di-tert-butyl-4-hydroxy-phenyl)-2-(4-trifluoromethoxy-phenyl)-acrylonitrile, 3-(3,5-di-tert-butyl-4-hydroxy-phenyl)-2-(4-trifluoromethyl-phenyl)-acrylonitrile, 2-cyano-3-(3,5-di-tert-butyl-4-hydroxy-phenyl)-but-2-enoic acid ethyl ester, N-(4-chloro-phenyl)-2-cyano-3-(3,5-di-tert-butyl-4-hydroxy-phenyl)-acrylamide, (E)-3-(3,5-di-tert-butyl-4-hydroxy-phenyl)-2-methanesulfonyl-acrylonitrile, (E)-2-(4-chloro-benzenesulfonyl)-3-(3,5-di-tert-butyl-4-hydroxy-phenyl)-acrylonitrile, (E)-3-(3,5-di-tert-butyl-4-hydroxy-phenyl)-acrylonitrile (E)-2-benzenesulfonyl-3-(3,5-di-tert-butyl-4-hydroxy-phenyl)-acrylonitrile, (E)-3-(3,5-di-tert-butyl-4-hydroxy-phenyl)-2-(propane-2-sulfonyl)-acrylonitrile, 3-(3,5-di-tert-butyl-4-hydroxy-phenyl)-2-(2,5-dichloro-benzenesulfonyl)-acrylonitrile, 3-(3,5-di-tert-butyl-4-hydroxy-phenyl)-2-(2,4 -dichloro-benzenesulfonyl)-acrylonitrile, 3-(3,5-di-tert-butyl-4-hydroxy-phenyl)-2-(hexane-1-sulfonyl)-acrylonitrile, 2-(4-bromo-benzenesulfonyl)-3-(3,5-di-tert-butyl-4-hydroxy-phenyl)-acrylonitrile, 2-(3-bromo-benzenesulfonyl)-3-(3,5-di-tert-butyl-4-hydroxy-phenyl)-acrylonitrile, 5-bromo-3-tert-butyl-N-(2-chloro-4-cyanophenyl)-2-hydroxybenzamide, 5-bromo- 3-tert-butyl-N-(4-cyanophenyl)-2-hydroxybenzamide, 3-bromo-5-tert-butyl-6-hydroxy-2-methyl-N-(2-trifluoromethylphenyl)benzamide, 2-(2-bromo-1H-indol-3-ylmethylene)malononitrile, 2-(7-bromo-2-methyl-1H-indol-3-ylmethylene)malononitrile, 2-(5-bromo-2-methyl-1H-indol-3-ylmethylene)malononitrile, pharmaceutically acceptable salts and derivatives thereof and mixtures thereof.

[0103] Clinical parameters and / or anthropometric measures are selected from the group consisting of: weight, body mass index, % fat, height, muscle, water, visceral fat, bone, metabolism, protein, obesity level, body age, fat-free mass, oxygenation, body oxygenation quantified in urine, vitamins and minerals, blood glucose, blood pressure, LDL cholesterol, HDL cholesterol, triglycerides, urine glucose, step counter, heart rate, fasting blood glucose, post-load blood glucose, total cholesterol, total bilirubin, alanine aminotransferase, aspartate aminotransferase and / or body temperature.

[0104] Devices (140) for measuring clinical parameters and / or anthropometric indices include, but are not limited to: scales, ORPs, vitamin bars, blood glucose meters, blood oximeters, smart watches, smart bracelets, smart clothing, patches, tattoos, implants, hearing aids, helmets, electrodes, chest straps, pedometers and / or medical devices and equipment for quantifying biochemical parameters.

Claims

1. A method for measuring, diagnosing, treating and managing metabolic syndrome using an electronic device, comprising administering a pharmaceutical product to a patient (100) in need thereof to prevent metabolic syndrome and related conditions or reduce their risk, characterized in that The method comprises: (a) collecting (101) and storing in a database (103) patient identification information (102a) and / or physical measurement information, clinical parameters and / or anthropometric indicators (102c) for incorporation into a medical record (102b); (b) connecting the patient (100) to a healthcare professional (110) specializing in metabolic syndrome and related conditions (111) to assess their health status; (c) indicating the patient's health condition (111b) and recording it in the medical record (102b); (d) explaining to the patient the indications of (111c) for treating the metabolic syndrome and / or related disorders or for preventing the metabolic syndrome and / or related disorders; (e) providing (121a) a pharmaceutical composition (130) having a drug product useful for preventing, alleviating or controlling metabolic syndrome and / or related disorders to a patient (100) in need thereof through a pharmacy (120); (f) providing (121b) through a pharmacy (120) to a patient (100) in need thereof supplies (140a) or measuring devices (140) for preventing, alleviating or controlling metabolic syndrome and / or related conditions; (g) connecting (151) one or more devices (140b) for measuring clinical parameters and / or anthropometric indices using an interactive user interface (150); (h) measuring (141), recording (142) and storing (143) in said database (103) the collected clinical parameters and / or anthropometric indicators (102c); (i) monitoring (112) data of clinical parameters and / or anthropometric measures (102c) of the patient (100) by a healthcare professional (110) in the field of metabolic syndrome and related conditions to assess the patient's health status; (j) adjusting or maintaining the indication for treating metabolic syndrome and / or related disorders or for preventing metabolic syndrome and / or related disorders in the patient (113); (k) Optionally, the health care professional (110) provides assistance (114) to the patient (100) within a specified time period or upon request of the patient or the health care professional.

2. A method for measuring, diagnosing, treating and managing metabolic syndrome using an electronic device, comprising administering a pharmaceutical product to a patient in need thereof to prevent metabolic syndrome and related conditions or reduce their risk, characterized in that The method comprises: (a) providing (121a) a pharmaceutical composition (130) having a pharmaceutical product useful for preventing, alleviating or controlling metabolic syndrome and / or related conditions to the patient (100) based on the patient identification information (102a) and body measurement information (102c) previously stored in a database (103) and / or the patient's medical record (102b); (b) monitoring (112) clinical parameters and / or anthropometric data of the patient by a healthcare professional (110) specializing in metabolic syndrome and related conditions to assess the patient's health status using an interactive user interface (150) connected to one or more devices for measuring clinical parameters and / or anthropometric data, wherein the interactive user interface (150) records (142) and stores (143) the clinical parameters and / or anthropometric data.

3. A method for measuring, diagnosing, treating and managing metabolic syndrome using an electronic device, comprising administering a pharmaceutical product to a patient receiving treatment for prevention, alleviation or control of metabolic syndrome and / or related conditions, characterized in that The method comprises: (a) collecting (101) and storing in a database (103) patient identification information (102a) and / or physical measurement information, clinical parameters and / or anthropometric indicators (102c) for incorporation into a medical record (102b); (b) providing (121a) a pharmaceutical composition (130) having a pharmaceutical product useful for preventing, alleviating or controlling metabolic syndrome and / or related conditions to a patient (100) in need thereof through a pharmacy (120) based on the patient identification information (102a) and the patient clinical parameters and / or anthropometric index information (102c) previously stored in a database and / or the patient's medical record (102b); (c) measuring (141), recording (142) and storing (143) in the database (103) clinical parameters and / or anthropometric measures (102c) of the patient collected during treatment; (d) monitoring (112) data of clinical parameters and / or anthropometric measures (102c) of the patient (100) by a healthcare professional (110) in metabolic syndrome and related conditions to assess the patient's health status; (e) adjusting or maintaining the indication for treating the metabolic syndrome and / or related disorders suffered by the patient or for preventing the metabolic syndrome and / or related disorders (113).

4. A method for measuring, diagnosing, treating and managing metabolic syndrome using an electronic device, comprising administering a pharmaceutical product to a patient in need thereof to prevent metabolic syndrome and related conditions or reduce their risk, characterized in that The method comprises: (a) connecting the patient (100) to a healthcare professional (110) specializing in metabolic syndrome and related conditions (111) to assess their health status; (b) indicating the patient's health condition (111b) and recording it in the medical record (102b); (c) explaining to the patient the indications of (111c) for treating metabolic syndrome and / or related disorders or for preventing metabolic syndrome and / or related disorders; (d) providing (121a) a pharmaceutical composition (130) having a drug product useful for preventing, alleviating or controlling metabolic syndrome and / or related disorders to a patient (100) in need thereof through a pharmacy (120); (e) recording (142) and storing (143) in said database (103) body measurements, clinical parameters and / or anthropometric indicators (102c) collected from said patient during treatment; (f) monitoring (112) data of clinical parameters and / or anthropometric measures (102c) of the patient (100) by a healthcare professional (110) in metabolic syndrome and related conditions to assess the patient's health status; (g) adjusting or maintaining the indication for treating the metabolic syndrome and / or related disorders suffered by the patient or for preventing the metabolic syndrome and / or related disorders (113).

5. A method for measuring, diagnosing, treating and managing metabolic syndrome using an electronic device, comprising administering a pharmaceutical product to a patient in need thereof to prevent metabolic syndrome and related conditions or reduce their risk, characterized in that The method comprises: (a) providing (121a) a pharmaceutical composition (130) having a drug product useful for preventing, alleviating or controlling metabolic syndrome and / or related disorders to a patient (100) in need thereof through a pharmacy (120); (b) providing (121b) through a pharmacy (120) to a patient (100) in need thereof supplies (140a) or support equipment (140b) for preventing, alleviating or controlling metabolic syndrome and / or related conditions; (c) connecting (151) one or more devices (140b) for measuring clinical parameters and / or anthropometric indices using an interactive user interface (150); (d) measuring (141), recording (142) and storing (143) in a database (103) the collected clinical parameters and / or anthropometric measures (102c); (e) monitoring (112) clinical parameters and / or anthropometric measurements (102c) data of the patient (100) by a healthcare professional (110) in metabolic syndrome and related conditions to assess the patient's health status; (f) adjusting or maintaining the indication for treating the metabolic syndrome and / or related disorders suffered by the patient or for preventing the metabolic syndrome and / or related disorders (113).

6. A method for measuring, diagnosing, treating and managing metabolic syndrome using an electronic device, comprising administering a drug to a patient in need thereof to prevent metabolic syndrome and related conditions or reduce their risk, characterized in that, The method comprises: (a) providing (121a) a pharmaceutical composition (130) having a drug product useful for preventing, alleviating or controlling metabolic syndrome and / or related disorders to a patient (100) in need thereof through a pharmacy (120); (b) connecting (151) one or more devices (140b) for measuring clinical parameters and / or anthropometric indices using an interactive user interface (150); (c) measuring (141), recording (142) and storing (143) in a database (103) the collected clinical parameters and / or anthropometric measures (102c); (d) monitoring (112) clinical parameters and / or anthropometric measurements (102c) data of the patient (100) by a healthcare professional (110) in metabolic syndrome and related conditions to assess the patient's health status; (e) adjusting or maintaining the indication for treating the metabolic syndrome and / or related disorders suffered by the patient or for preventing the metabolic syndrome and / or related disorders (113).

7. A system for monitoring at least one clinical parameter and / or anthropometric index of a patient (100) in need thereof using an electronic device associated with a device for measuring clinical parameters and / or anthropometric indexes to prevent or reduce the risk of metabolic syndrome and related conditions, characterized in that The system comprises: (a) a patient monitoring module installed in the patient's electronic device (160a); (b) at least one device (140) for measuring clinical parameters and / or anthropometric indices, connected to the patient's electronic device (160a); (c) a communication device (180) between the patient's electronic device (160a) and a device (140) for measuring clinical parameters and / or anthropometric indices; The patient monitoring module is configured to: (i) collect (101) patient identification information (102a) and / or body measurement information (102c); (ii) (141), record (142) and store (143) in a database (103) the collected patient clinical parameters and / or anthropometric indicators (102c); (iii) store the information in the database (103) for incorporation into the medical record (102b); (iv) associate the patient (100) with metabolic syndrome and related (v) providing (121a) to the patient (100) in need thereof, through a pharmacy (120), with medicines that are useful for preventing, alleviating or controlling metabolic syndrome and / or related conditions, to the patient (100); (v) providing (121b) to the patient (100) a medicine that is useful for preventing, alleviating or controlling metabolic syndrome and / or related conditions, and (v) providing ... The invention relates to a pharmaceutical composition (130) of a pharmaceutical product useful for treating metabolic syndrome and / or related conditions, and supplies (140a) or supporting equipment (140b); (vi) establishing a connection (151) with at least one device (140) for measuring clinical parameters and / or anthropometric indices; (vii) measuring (141), recording (142) and storing (143) in the database (103) clinical parameters and / or anthropometric indices (102c) obtained from at least one device (140) for measuring clinical parameters and / or anthropometric indices; (vii) allowing a healthcare professional (110) in the field of metabolic syndrome and related conditions to access (170) the patient's medical record to assess the patient's health status and adjust or maintain treatment indications (113); and optionally, (ix) establishing communication (114) between the patient (100) and the healthcare professional (110) within a specified time period or upon request of the patient or the healthcare professional.

8. A system for monitoring at least one clinical parameter and / or anthropometric index of a patient (100) in need thereof using an electronic device to prevent or reduce the risk of metabolic syndrome and related conditions, characterized in that: The system comprises: (a) a device and interface (160a) for inputting patient identification information and / or body measurement information into a database; (b) equipment and interfaces (160b) for collecting and storing patient identification information and / or physical measurement information in a database for incorporation into medical records; (c) access means (170) for communication between the patient and a health care professional in the area of ​​metabolic syndrome and related conditions to assess the patient's health status; (d) means (170a) for indicating to said patient the state of his health and recording it in said medical record; (e) means for explaining to the patient the indications for treating the metabolic syndrome and / or related disorders or for preventing the metabolic syndrome and / or related disorders (170b); (f) a device (120) for providing (121a) a pharmaceutical composition comprising a pharmaceutical product useful for preventing, alleviating or controlling metabolic syndrome and / or related disorders to a patient in need thereof; (g) devices for providing (121b) supplies or support equipment for preventing, alleviating or controlling metabolic syndrome and / or related conditions to patients in need thereof; (h) means (152) for connecting one or more devices for measuring clinical parameters and / or anthropometric measures using an interactive user interface; (i) a database (103) for recording and storing collected clinical parameters and / or anthropometric measurements; (j) means for monitoring (112) the patient's clinical parameters and / or anthropometric data to assess their health status by a healthcare professional in the field of metabolic syndrome and related conditions; (k) access means for the health care professional to adjust or maintain an indication (113) for treating the metabolic syndrome and / or related conditions suffered by the patient or for preventing the metabolic syndrome and / or conditions; (l) Optionally, access means for establishing communications (114) between the patient and the healthcare professional within a specified time period or upon request by the patient or the healthcare professional.

9. A method for measuring, diagnosing, treating and managing metabolic syndrome using an electronic device, comprising administering a pharmaceutical product to a patient in need thereof to prevent metabolic syndrome and related conditions or reduce their risk, characterized in that, The method comprises: (a) providing a monitoring system (200) for treatment or prevention to the patient and health care professionals, the system comprising at least: a device and interface (160a) for inputting patient identification information and / or body measurement information into a database; a device and interface (160b) for collecting and storing patient identification information and / or body measurement information in a database for incorporation into a medical record; an access device (170) for communication between the patient and health care professionals in the field of metabolic syndrome and related conditions to assess the patient's health status; a device (170a) for indicating the patient's health status to the patient and recording it in the medical record; a device (170b) for explaining to the patient the indications for treating the metabolic syndrome and / or related conditions or for preventing the metabolic syndrome and / or related conditions; a device (121a) for providing a patient in need thereof with a pharmaceutical composition having a pharmaceutical product useful for preventing, alleviating or controlling the metabolic syndrome and / or related conditions; 0); means for providing (121b) supplies or support equipment for preventing, alleviating or controlling metabolic syndrome and / or related conditions to a patient in need thereof; means for connecting one or more devices for measuring clinical parameters and / or anthropometric indices using an interactive user interface (152); a database (103) for recording and storing collected clinical parameters and / or anthropometric indices; means for monitoring (112) the patient's clinical parameter and / or anthropometric data by a health care professional in the field of metabolic syndrome and related conditions to assess their health status; access means for the health care professional to adjust or maintain indications (113) for treating the patient's metabolic syndrome and / or related conditions or for preventing metabolic syndrome and / or related conditions; optionally, access means for establishing communication (114) between the patient and the health care professional within a specified time period or upon request of the patient or the health care professional; (b) providing the patient (100) with a pharmaceutical composition (130) having a pharmaceutical product useful for preventing, alleviating or controlling metabolic syndrome and / or related disorders based on the patient's identity information and body measurement information previously stored in a database or the patient's medical record; (c) monitoring clinical parameters and / or anthropometric data of the patient by a healthcare professional (110) specializing in metabolic syndrome and related conditions using an interactive user interface connected to one or more devices for measuring clinical parameters and / or anthropometric data to assess the patient's health status.

10. A method for measuring, diagnosing, treating and managing metabolic syndrome using an electronic device according to claims 1 to 6, comprising administering a pharmaceutical product to a patient (100) in need thereof to prevent or reduce the risk of metabolic syndrome and related conditions, wherein: The body measurements, clinical parameters and / or anthropometric indicators are selected from: weight, body mass index, % fat, height, muscle, water, visceral fat, bone, metabolism, protein, obesity level, body age, fat-free body mass, oxygenation, body oxygenation quantified in urine, vitamins and minerals, blood glucose, blood pressure, LDL cholesterol, HDL cholesterol, triglycerides, urine glucose, step counter, heart rate, fasting blood glucose, post-load blood glucose, total cholesterol, total bilirubin, alanine aminotransferase, aspartate aminotransferase and / or body temperature.

11. A method for measuring, diagnosing, treating and managing metabolic syndrome using an electronic device according to claims 1 to 6, comprising administering a pharmaceutical product to a patient (100) in need thereof to prevent or reduce the risk of metabolic syndrome and related conditions, wherein: The measuring device (140) is selected from: a scale, an ORP, a vitamin bar, a blood glucose meter, a blood oximeter, a smart watch, a smart bracelet, smart clothing, a patch, a tattoo, an implant, a hearing aid, a helmet, an electrode, a chest strap, a pedometer, and a medical device for quantifying biochemical parameters.

12. A method for measuring, diagnosing, treating and managing metabolic syndrome using an electronic device according to claims 1 to 6, comprising administering a drug to a patient (100) in need thereof to prevent metabolic syndrome and related conditions or reduce the risk thereof, wherein: The pharmaceutical composition (130) having a drug product useful for preventing, reducing or controlling metabolic syndrome and / or related conditions is selected from: oxidative phosphorylation chemical uncouplers, tyrosine phosphorylation inhibitor AG17, orlistat, L-carnitine, benzphetamine, phendimetrazine, diethylpropion, liraglutide, naltrexone, phentermine, topiramate, glibenclamide, metformin, acarbose, canagliflozin, dapagliflozin, saxagliptin, dulaglutide, empagliflozin, exenatide, lixisenatide, semaglutide, CBD, sibutramine, hydroxycitrate, coenzyme Q10, chromium picolinate, gamma -linolenic acid, resveratrol, omega-3 fatty acids, antioxidants, vitamins, vitamin B, vitamin C, adrenal extract, pantothenic acid, turmeric, bayberry bark, wax bayberry, indica, tea, cocoa, emblica, paraguay holly, cascara bark, cascara bosch, acacia arabica, persimmon, blueberry leaf, grape seed, willow leaf ragwort, St. John's wort, sweet kudzu vine, capers, gymnema, elderberry, elderberry, citrus aurantium, coffee beans, Hainan syrup, rosemary, ginger, bean tea cassia, square stem green purple kudzu, kidney bean, licorice root, fenugreek, yohimbe, white willow, cordyceps, ashwagandha, astragalus, human ginseng, schisandra, siberian ginseng, asian ginseng, indian myrrh, bitter melon, garcinia cambogia, marshmallow, bougainvillea, alfalfa, valerian, damiana, sambucus nigra, capsicum, allium, calcium myristate, magnesium myristate, tetradecylthioacetic acid (TTA), thyroid hormone or its precursor, thyroid function enhancer, Krebs cycle metabolite, one or more endogenous uncoupling proteins such as UCP-1, UCP-2, UCP-3, PUMP (plant uncoupling mitochondrial protein) or one or more precursors, one or more agonists or enhancers thereof, leucine, valerian amino acid, isoleucine, glutamine, proline, tyrosine, conjugated linoleic acid, adrenaline secretion enhancers, fatty acids or esters, beta agonists, glucagon, abutamine, vasopressin, ubiquinone, coenzyme 01, coenzyme Q2, melatonin, fatty acid esters of estrogens such as oleylestrone, glucomannan, menthol, peppermint essential oil, thyme essential oil, elemental sulfur and polyunsaturated fatty acid, insulin or insulin analogs and orally active hypoglycemic agents; acetohexamide, amoxicillin, chlorpropamide, glibenclamide, glibourea, gliclazide, glimepiride, glipizide, tolazamide and tolbutamide;2R,3R,4R,5S)-1-(2-hydroxyethyl)-2-(hydroxymethyl)piperidin-3,4,5-triol or miglitol) (1S,2S,3R,4S,5S)-5-(1,3-dihydroxypropan-2-ylamino)-1-(hydroxymethyl)-cyclohexane-1,2,3,4-tetraol), (RS)-5-[4-(2-[methyl(pyridin-2-yl)amino]ethoxy)benzyl]thiazolidine-2,4-dione, (RS)-5-(4-[2-(5-ethylpyridin-2-yl)ethoxy]benzyl)thiazolidine-2,4-dione, 5-[(4-[2-([6-(4-methoxyphenoxy)pyrimidin-4-yl]- methylamino)ethoxy]phenyl-)methyl]-1,3-thiazolidine-2,4-dione, (RS)-5-(4-[(6-hydroxy-2,5,7,8-tetramethylchroman-2-yl)methoxy]benzyl)thiazolidine-2,4-dione; (S)-(+)-2-ethoxy-4-[2-(3-methyl-1-[2-(piperidin-1-yl)phenyl]butylamino)-2-oxyylideneethyl]benzoic acid, 3-phenyl-2-[(4-propan-2-ylcyclohexanecarbonyl)amino]propionic acid, (2S)-2-benzyl-4-[(3aR,7aS)-octahydro-2H-isoindol-2-yl]-4-oxyylidenebutanoic acid, L-ornithine, L-tyrosine, L-tryptophan, L-phenylalanine, conjugated linoleic acid, gamma-linolenic acid, chromium picolinate, glucose tolerance factor, vanadyl sulfate, gymnema, bromelain, pancreatin, papain, coenzyme Q10, curcumin, berberis, bearberry, silymarin, angustifolia, choline, inositol, human growth hormone, DHEA (dehydroepiandrosterone), caffeine, xanthenes (such as fucoxanthin), kola nut, plantain, mate, guarana, ginseng, medium chain triglycerides, hydroxycitric acid (HCA), kelp, lecithin, dihydroxyacetone, pyruvate, creatine, iodine, niacin, fucus, white bean extract, glucomannan, chitosan, resveratrol, resveratrol derivatives, vitamin D , hCG, capsaicin, chia, Hoodia cactus, apple cider vinegar, coconut oil, bitter orange, vitamin B, fluoxetine, chitosan, chromium picolinate, conjugated linoleic acid (CLA), glucomannan, green tea extract, green coffee extract, guar gum, Hoodia cactus, 7-keto-DHEA, DHEA, ephedra, bitter orange, turmeric, ginger, root powder, apple cider vinegar, calcium, hesperidin, gynostemma pentaphyllum total saponin, extract flaxseed oil, orange peel powder, thiamine, ashwagandha extract, coffee extract, L-theanine, choline bitartrate, red mango extract, white kidney bean extract, cane coffee robusta extract, acetyl-L carnitine, garcinia, turmeric extract, coconut oil, forskolin; Extract, black pepper extract paroxetine, citalopram, bupropion, topiramate, eicopipan, naltrexone, peptide YY3-36, leptin, amphetamine, amphetamine, phentermine, mazindol phendimetrazine, bupropion, fenfluramine, dexfenfluramine, pharmaceutically acceptable salts and derivatives thereof, and mixtures thereof.

13. The method for measuring, diagnosing, treating and managing metabolic syndrome using an electronic device according to claim 12, comprising administering a pharmaceutical product to a patient (100) in need thereof to prevent or reduce the risk of metabolic syndrome and related conditions, wherein: The oxidative phosphorylation chemical uncoupler is selected from: 4,4-bis-(4-hydroxy-3-nitrophenyl)-pentanoic acid, 4-methoxy-2-nitrophenol, 4-hydroxy-3-nitroacetophenone, 7-hydroxy-4-methyl-8-nitro-chromen-2-one, 3-tert-butyl-5-chloro-N-(2-chloro-4-nitrophenyl)-2-hydroxy-6-methyl-benzamide, N-1-[4-cyano-3-(trifluoromethyl)phenyl]-3,5- Bis(trifluoromethyl)benzamide, N-(4-cyanophenyl)benzamide, 2′-chloro-1-hydroxy-4′-nitro-2-naphthoic acid anilide, N-(2-chloro-4-bromophenyl)-5-bromosalicylic acid anilide, N-(2-chloro-4-nitrophenyl)-3-tert-butyl-6-methylsalicylic acid anilide, (3,5-di-tert-butyl-4-hydroxybenzyl)triphenylphosphonium bromide, (3,5-di-tert-butyl-4-hydroxybenzyl)tricyclohexylphosphonium bromide, (3,5-di-tert-butyl-4-hydroxybenzyl)tributylphosphonium bromide, (3,5-di-tert-butyl-4-hydroxybenzyl)trioctylphosphonium bromide, 2-cyano-3-(3,5-di-tert-butyl-4-hydroxyphenyl)-ethyl acrylate, 2-(3,5-di-tert-butyl-4-hydroxy-benzylidene)-malonic acid diethyl ester, 2-amino-S-[(3,5-di-tert-butyl-4-hydroxy-benzylidene)-amino]-but-2-enedinitrile, 2-(3,5-di-tert-butyl-4-hydroxy-benzylidene)-indan-1,3-dione, 2-[[2-(4-chlorophenyl)-1H-indol-3-yl]methylene]malononitrile, 2-(4-chlorophenyl)-indole, N-(2,4,5-trichlorophenyl) salicylanilide, 2,3-dimethyl-5-cyano-7-ethylindole, 4-bromo-2-(4-chlorophenyl)-5-trifluoromethyl-1H-pyrrole-3-carbonitrile, N-(3 -cyano-4-phenylthio-phenyl)-3-trifluoromethyl-benzamide, 2,4-dinitrophenol, carbonyl cyanide p-trifluoromethoxy-phenylhydrazone, 2-(5,7-dimethyl-1H-indol-3-ylmethylene)-malononitrile, 2-(5-bromo-1H-indol-3-ylmethylene)-malononitrile, 2-((5-chloro-1H-indol-3-yl)methylene)malononitrile, 2-((5-methyl-1H-indol-3-yl)methylene)malononitrile, 2-((5-methyl-1H-indol-3-yl)methylene)malononitrile, 2-(2-phenyl-3-indolylmethylene)-malononitrile, 2-(2-chloro-1H-indol-3-yl 2-(5-nitro-1H-indol-3-ylmethylene)-malononitrile, 2-(2-methyl-5-nitro-1H-indol-3-ylmethylene)-malononitrile, 3-bromo-5-tert-butyl-N-(2-chloro-4-nitro-phenyl)-6-hydroxy-2-methyl-benzamide, N-(2-chloro-4-nitro-phenyl)-2-hydroxy-3-isopropyl-benzamide, N-(2-chloro-4-nitro-phenyl)-2-hydroxy-3-isopropyl-6-methyl-benzamide, 3,5-di-tert-butyl-N-(2-chloro-4-nitrophenyl)-2-hydroxy-benzamide, 3-bromo-N-(2-chloro-4-nitrophenyl)-2-hydroxy-3-isopropyl-6-methyl-benzamide 3-tert-butyl-5-chloro-N-(4-chloro-3-trifluoromethyl-phenyl)-2-hydroxy-6-methyl-benzamide, 3-tert-butyl-5-chloro-N-(4-cyano-3-trifluoromethyl-phenyl)-2-hydroxy-6-methyl-benzamide, 2-hydroxy-biphenyl-3-carboxylic acid (2-chloro-4-nitro-phenyl)-amide, 3-tert-butyl-N-(2-chloro-4-nitro-phenyl)-2-hydroxy-5-methyl-benzamide, N-(2-chloro-4-nitro-phenyl)-2-hydroxy-6-isopropyl-3-methyl-benzamide, N-(3,3-tert-butyl-5-chloro-2-hydroxy-6-methyl-benzamide, 3-tert-butyl-5-chloro-N-(2-fluoro-5-trifluoromethyl-phenyl)-2-hydroxy-6-methyl-benzamide, 3-tert-butyl-5-chloro-2-hydroxy-6-methyl-N-(4-nitro-3-trifluoromethyl-phenyl)-benzamide, 3-tert-butyl-5-chloro-2-hydroxy-6-methyl-N-(4-nitro-2-trifluoromethyl-phenyl)-benzamide, 3-bromo-5-tert-butyl-N-(2-chloro-4-cyano-phenyl)-6-hydroxy-2-methyl-benzamide, 3-bromo-5-tert-butyl-N-(2-chloro-5-trifluoromethyl-phenyl)-6-hydroxy-2 -methyl-benzamide, 3-bromo-5-tert-butyl-N-(2,4-dichloro-phenyl)-6-hydroxy-2-methyl-benzamide, 3-bromo-5-tert-butyl-N-(2,4-dichloro-6-nitro-phenyl)-6-hydroxy-2-methyl-benzamide, 3-bromo-5-tert-butyl-N-(2,6-dichloro-4-nitro-phenyl)-6-hydroxy-2-methyl-benzamide, 3-bromo-5-tert-butyl-N-{5-chloro-4-[(4-chloro-phenyl)-cyano-methyl]-2-methyl-phenyl}-6-hydroxy-2-methyl-benzamide, 3-bromo-6-hydroxy-5-isopropyl-2-methyl-N-(4-nitro-2-trifluoromethyl-phenyl)-benzamide, 3-bromo- 5-tert-Butyl-6-hydroxy-2-methyl-N-(4-nitro-2-trifluoromethyl-phenyl)-benzamide, 3-tert-Butyl-2-hydroxy-6-methyl-N-(4-nitro-2-trifluoromethyl-phenyl)-benzamide, 3-bromo-N-(2-bromo-3,5-bis-trifluoromethyl-phenyl)-5-tert-butyl-6-hydroxy-2-methylbenzamide, N-(2,5-bis-trifluoromethyl-phenyl)-3-bromo-5-tert-butyl-6-hydroxy-2-methyl-benzamide, 3-bromo-5-tert-butyl-N-(2,4-dichloro-6-trifluoromethyl-phenyl)-6-hydroxy-2-methylbenzamide, 3-bromo-5-tert-butyl-6-hydroxy-N-(4-isopropyl-2-trifluoromethyl -phenyl)-2-methyl-benzamide, N-(3,5-bis-trifluoromethyl-phenyl)-3-fluoro-5-trifluoromethyl-benzamide, 3-fluoro-N-(4-nitro-3-trifluoromethyl-phenyl)-5-trifluoromethyl-benzamide, N-(3,5-bis-trifluoromethyl-phenyl)-3-fluoro-4-trifluoromethyl-benzamide, 4-fluoro-N-(4-nitro-3-trifluoromethyl-phenyl)-3-trifluoromethyl-benzamide, 3-(3,5-di-tert-butyl-4-hydroxy-phenyl-2-(2,2-dimethyl-propionyl)-acrylonitrile, 2-acetyl-3-(3,5-di-tert-butyl-4-hydroxy-phenyl)-ethyl acrylate, 2-(3,5-dimethyl-4-hydroxy-benzamide, 2-(3,5-dimethyl-4-hydroxy-benzylidene)-malononitrile, 2-(3,5-dimethyl-4-hydroxy-benzylidene)-malononitrile, 2,6-di-tert-butyl-4-nitro-phenol, 2-tert-butyl-4,6-dinitro-phenol, 3-(3,5-di-tert-butyl-4-hydroxy-phenyl)-2-pyridin-2-yl-acrylonitrile, 2-[1-(3,5-di-tert-butyl-4-hydroxy-phenyl)-ethylidene]-malononitrile, 3-(3,5-di-tert-butyl-4-hydroxybenzylidene)-2-(diethylphosphonate)-acrylonitrile, 3-(3,5-di-tert-butyl-4-hydroxy-phenyl)-2-(4-nitro-phenyl)- )-acrylonitrile, 3-(3,5-di-tert-butyl-4-hydroxy-phenyl)-2-pyridin-4-yl-acrylonitrile, 2-(3,5-bis-trifluoromethyl-phenyl)-3-(3,5-di-tert-butyl-4-hydroxy-phenyl)-acrylonitrile, 3-(3,5-di-tert-butyl-4-hydroxy-phenyl)-2-(4-trifluoromethoxy-phenyl)-acrylonitrile, 3-(3,5-di-tert-butyl-4-hydroxy-phenyl)-2-(4-trifluoromethyl-phenyl)-acrylonitrile, 2-cyano-3-(3,5-di-tert-butyl-4-hydroxy-phenyl)-but-2-enoic acid ethyl ester, N-(4-chloro- (E)-2-cyano-3-(3,5-di-tert-butyl-4-hydroxy-phenyl)-acrylamide, (E)-3-(3,5-di-tert-butyl-4-hydroxy-phenyl)-2-methanesulfonyl-acrylonitrile, (E)-2-(4-chloro-benzenesulfonyl)-3-(3,5-di-tert-butyl-4-hydroxy-phenyl)-acrylonitrile, (E)-3-(3,5-di-tert-butyl-4-hydroxyphenyl)-2-(4-fluoro-benzenesulfonyl)-acrylonitrile, (E)-2-benzenesulfonyl-3-(3,5-di-tert-butyl-4-hydroxy-phenyl)-acrylonitrile, (E)-3-(3,5-di-tert-butyl-4-hydroxy-phenyl)-acrylonitrile, (E)-3-(3,5-di-tert-butyl-4-hydroxy-phenyl)-acrylonitrile 3-(3,5-di-tert-butyl-4-hydroxy-phenyl)-2-(2,5-dichloro-benzenesulfonyl)-acrylonitrile, 3-(3,5-di-tert-butyl-4-hydroxy-phenyl)-2-(2,4-dichloro-benzenesulfonyl)-acrylonitrile, 3-(3,5-di-tert-butyl-4-hydroxy-phenyl)-2-(hexane-1-sulfonyl)-acrylonitrile, 2-(4-bromo-benzenesulfonyl)-3-(3,5-di-tert-butyl-4-hydroxy-phenyl)-acrylonitrile, 2-(3 ...5-di-tert-butyl-4-hydroxy-phenyl)-acrylonitrile, 5-bromo-3-tert-butyl-N-(2-chloro-4-cyanophenyl)-2-hydroxybenzamide, 5-bromo-3-tert-butyl-N-(4-cyanophenyl)-2-hydroxybenzamide, 3-bromo-5-tert-butyl-6-hydroxy-2-methyl-N-(2-trifluoromethylphenyl)benzamide, 2-(2-bromo-1H-indol-3-ylmethylene)malononitrile, 2-(7-bromo-2-methyl-1H-indol-3-ylmethylene)malononitrile, 2-(5-bromo-2-methyl-1H-indol-3-ylmethylene)malononitrile, pharmaceutically acceptable salts and derivatives thereof and mixtures thereof.

14. The method for measuring, diagnosing, treating and managing metabolic syndrome using an electronic device according to claim 1, comprising administering a pharmaceutical product to a patient (100) in need thereof to prevent or reduce the risk of metabolic syndrome and related conditions, wherein: The pharmaceutical composition (130) with a drug product includes a drug product for preventing, alleviating or controlling hypertension, selected from: alprenolol, atenolol, timolol, pindolol, propranolol and metoprolol, ACE (angiotensin converting enzyme) inhibitors such as benazepril, captopril, enalapril, fosinopril, lisinopril, quinapril and ramipril, calcium channel blockers such as nifedipine, felodipine, nicardipine, isradipine, nimodipine, diltiazem and verapamil, and [α]-blockers such as doxazosin, urapidil, prazosin and terazosin, their pharmaceutically acceptable salts and derivatives thereof and mixtures thereof.

15. The method for measuring, diagnosing, treating and managing metabolic syndrome using an electronic device according to claim 1, comprising administering a pharmaceutical product to a patient (100) in need thereof to prevent or reduce the risk of metabolic syndrome and related conditions, wherein: The pharmaceutical composition (130) with a drug comprises a drug product for preventing, alleviating or controlling hyperglycemia (type I diabetes or type II diabetes) selected from: oxidative phosphorylation chemical uncouplers or derivatives thereof, agents acting on the ATP-dependent potassium channels of pancreatic [β] cells, biguanides, imidazolines, [α]-glucosidase inhibitors, meglitinides, oxadiazolidinediones, thiazolidinediones, insulin sensitizers, sulfonylureas, potassium channel blockers such as nateglinide or BTS-67582, glucagon antagonists, DPP-IV (dipeptidyl peptidase-IV) inhibitors, PTPase (protein tyrosine phosphatase) inhibitors, glucose kinase kinase inhibitors active agents, inhibitors of liver enzymes involved in stimulating gluconeogenesis and / or glycogenolysis, regulators of glucose uptake, GSK-3 (glycogen synthase kinase-3) inhibitors, compounds that alter lipid metabolism such as anti-hyperlipidemic and hypolipidemic drugs, compounds that reduce food intake, and PPAR agonists; for example: tyrosine phosphorylation inhibitor AG17, tyrosine phosphorylation inhibitor A9, insulin and insulin analogs, tolbutamide, chlorpropamide, tolazamide, glibenclamide, glipizide, glimepiride, gliclazide or glyburide, metformin, repaglinide or senaglinide / nateglinide, troglitazone, pioglitazone, rosiglitazone, isoglitazone, darglitazone, englitazone, GI 262570, YM-440, MCC-555, JTT-501, AR-H039242, KRP-297, GW-409544, CRE-16336, AR-H, voglibose, emiglitate, miglitol or acarbose, tolbutamide, glibenclamide, glipizide, gliclazide, BTS-67582 or repaglinide, nateglinide, colestiamide, colestipol, clofibrate, gemfibrozil, lovastatin, pravastatin, simvastatin, pharmaceutically acceptable salts and derivatives thereof and mixtures thereof.

16. A method for measuring, diagnosing, treating and managing overweight and obesity using an electronic device, comprising administering a pharmaceutical product to a patient (100) in need thereof to prevent overweight and obesity or reduce the risk thereof, characterized in that The method comprises: (a) collecting (101) and storing in a database (103) patient identification information (102a) and / or physical measurement information, clinical parameters and / or anthropometric indicators (102c) for incorporation into a medical record (102b); (b) connecting (111) the patient (100) with an overweight and obesity health care professional (110) to assess their health status; (c) indicating the patient's health condition (111b) and recording it in the medical record (102b); (d) explaining to the patient the indications of (111c) for treating the overweight and obesity suffered by the patient or for preventing overweight and obesity; (e) providing (121a) a pharmaceutical composition (130) having a pharmaceutical product useful for preventing, reducing or controlling overweight and obesity to a patient (100) in need thereof through a pharmacy (120); (f) providing (121b) through a pharmacy (120) to a patient (100) in need thereof supplies (140a) or measuring devices (140) for preventing, reducing or controlling overweight and obesity; (g) connecting (151) one or more devices (140b) for measuring clinical parameters and / or anthropometric indices using an interactive user interface (150); (h) measuring (141), recording (142) and storing (143) in said database (103) the collected clinical parameters and / or anthropometric indicators (102c); (i) monitoring (112) data of clinical parameters and / or anthropometric measures (102c) of the patient (100) by a health care professional (110) in the field of overweight and obesity to assess the patient's health status; (j) adjusting or maintaining the indication for treating overweight and obesity or for preventing overweight and obesity in the patient (113); (k) Optionally, the health care professional (110) provides assistance (114) to the patient (100) within a specified time period or upon request of the patient or the health care professional.

17. A method for measuring, diagnosing, treating and managing overweight and obesity using an electronic device, comprising administering a pharmaceutical product to a patient in need thereof to prevent overweight and obesity or reduce the risk thereof, characterized in that, The method comprises: (a) providing (121a) a pharmaceutical composition (130) having a pharmaceutical product useful for preventing, reducing or controlling overweight and obesity to the patient (100) based on the patient's identity information (102a) and body measurement information (102c) previously stored in a database (103) and / or the patient's medical record (102b); (b) monitoring (112) clinical parameters and / or anthropometric data of the patient by an overweight and obesity health care professional (110) using an interactive user interface (150) connected to one or more devices for measuring clinical parameters and / or anthropometric data to assess the patient's health status, wherein the interactive user interface (150) records (142) and stores (143) the clinical parameters and / or anthropometric data.

18. A method for measuring, diagnosing, treating and managing overweight and obesity using an electronic device, comprising administering a pharmaceutical product to a patient receiving treatment for prevention, reduction or control of overweight and obesity, characterized in that The method comprises: (a) collecting (101) and storing in a database (103) patient identification information (102a) and / or physical measurement information, clinical parameters and / or anthropometric indicators (102c) for incorporation into a medical record (102b); (b) providing (121a) a pharmaceutical composition (130) having a pharmaceutical product useful for preventing, reducing or controlling overweight and obesity to a patient (100) in need thereof through a pharmacy (120) based on the patient identification information (102a) and the patient clinical parameters and / or anthropometric index information (102c) previously stored in a database and / or the patient's medical record (102b); (c) measuring (141), recording (142) and storing (143) in the database (103) clinical parameters and / or anthropometric measures (102c) of the patient collected during treatment; (d) monitoring (112) data of clinical parameters and / or anthropometric measures (102c) of the patient (100) by a health care professional (110) in the field of overweight and obesity to assess the patient's health status; (e) adjusting or maintaining the indication for treating overweight and obesity or for preventing overweight and obesity in said patient (113).

19. A method for measuring, diagnosing, treating and managing overweight and obesity using an electronic device, comprising administering a pharmaceutical product to a patient in need thereof to prevent overweight and obesity or reduce the risk thereof, characterized in that, The method comprises: (a) connecting (111) the patient (100) with an overweight and obesity health care professional (110) to assess their health status; (b) indicating the patient's health condition (111b) and recording it in the medical record (102b); (c) explaining to the patient the indications of (111c) for treating the overweight and obesity suffered by the patient or for preventing overweight and obesity; (d) providing (121a) a pharmaceutical composition (130) having a pharmaceutical product useful for preventing, reducing or controlling overweight and obesity to a patient (100) in need thereof through a pharmacy (120); (e) recording (142) and storing (143) in said database (103) body measurements, clinical parameters and / or anthropometric indicators (102c) collected from said patient during treatment; (f) monitoring (112) data of clinical parameters and / or anthropometric measures (102c) of the patient (100) by a health care professional (110) in the field of overweight and obesity to assess the patient's health status; (g) adjusting or maintaining the indication for treating overweight and obesity or for preventing overweight and obesity in said patient (113).

20. A method for measuring, diagnosing, treating and managing overweight and obesity using an electronic device, comprising administering a pharmaceutical product to a patient in need thereof to prevent overweight and obesity or reduce the risk thereof, characterized in that, The method comprises: (a) providing (121a) a pharmaceutical composition (130) having a pharmaceutical product useful for preventing, reducing or controlling overweight and obesity to a patient (100) in need thereof through a pharmacy (120); (b) providing (121b) through a pharmacy (120) to a patient (100) in need thereof supplies (140a) or support equipment (140b) for preventing, reducing or managing overweight and obesity; (c) connecting (151) one or more devices (140b) for measuring clinical parameters and / or anthropometric indices using an interactive user interface (150); (d) measuring (141), recording (142) and storing (143) in a database (103) the collected clinical parameters and / or anthropometric measures (102c); (e) monitoring (112) clinical parameters and / or anthropometric measurements (102c) data of the patient (100) by a health care professional (110) in the field of overweight and obesity to assess the patient's health status; (f) adjusting or maintaining the indication for treating overweight and obesity or for preventing overweight and obesity in said patient (113).

21. A method for measuring, diagnosing, treating and managing overweight and obesity using an electronic device, comprising administering a drug to a patient in need thereof to prevent overweight and obesity or reduce the risk thereof, characterized in that, The method comprises: (a) providing (121a) a pharmaceutical composition (130) having a pharmaceutical product useful for preventing, reducing or controlling overweight and obesity disorders to a patient (100) in need thereof through a pharmacy (120); (b) connecting (151) one or more devices (140b) for measuring clinical parameters and / or anthropometric indices using an interactive user interface (150); (c) measuring (141), recording (142) and storing (143) in a database (103) the collected clinical parameters and / or anthropometric measures (102c); (d) monitoring (112) clinical parameters and / or anthropometric measurements (102c) of the patient (100) by an overweight and obesity healthcare professional (110) to assess the patient's health status; (e) adjusting or maintaining the indication for treating overweight and obesity or for preventing overweight and obesity in said patient (113).

22. A system for monitoring at least one clinical parameter and / or anthropometric index of a patient (100) in need thereof to prevent or reduce the risk of overweight and obesity using an electronic device associated with a device for measuring clinical parameters and / or anthropometric indexes, characterized in that The system comprises: (a) a patient monitoring module installed in the patient's electronic device (160a); (b) at least one device (140) for measuring clinical parameters and / or anthropometric indices, connected to the patient's electronic device (160a); (c) a communication device (180) between the patient's electronic device (160a) and a device (140) for measuring clinical parameters and / or anthropometric indices; Wherein, the patient monitoring module is configured to: (i) collect (101) patient identification information (102a) and / or anthropometric information (102c); (ii) (141), record (142) and store (143) in a database (103) the collected patient clinical parameters and / or anthropometric indicators (102c); (iii) store the information in the database (103) for incorporation into the medical record (102b); (iv) connecting (111) the patient (100) with an overweight and obesity health care professional (110) to assess the patient's health condition, indicating the patient's health condition (111b), recording it in the medical record (102b), and indicating (111c) to the patient the indications for treating the overweight and obesity or for preventing overweight and obesity; (v) providing (121a) a pharmaceutical composition (130) having a pharmaceutical product useful for preventing, reducing or controlling overweight and obesity, and supplies (140a) or supporting equipment (140b) to a patient (100) in need thereof through a pharmacy (120); (vi) establishing a connection (151) with at least one device (140) for measuring clinical parameters and / or anthropometric indices; (vii) measuring (141), recording (142) and storing (143) in the database (103) data from at least one device (140) for measuring clinical parameters and / or anthropometric indices and / or anthropometric measurements (102c) obtained by a device (140) for measuring and / or anthropometric measurements; (vii) allowing an overweight and obesity health care professional (110) to access (170) the patient's medical records to assess the patient's health status and adjust or maintain treatment indications (113); and optionally, (ix) establishing communication (114) between the patient (100) and the health care professional (110) within a specified time period or upon request of the patient or the health care professional.

23. A system for monitoring at least one clinical parameter and / or anthropometric index of a patient (100) in need thereof using an electronic device to prevent or reduce the risk of overweight and obesity, characterized in that The system comprises: (a) a device and interface (160a) for inputting patient identification information and / or body measurement information into a database; (b) equipment and interfaces (160b) for collecting and storing patient identification information and / or physical measurement information in a database for incorporation into medical records; (c) an access device (170) for communication between the patient and an overweight and obesity health care professional to assess the patient's health status; (d) means (170a) for indicating to said patient the state of his health and recording it in said medical record; (e) means (170b) for explaining to the patient the indications for treating the overweight and obesity suffered by the patient or for preventing overweight and obesity; (f) a device (120) for providing (121a) a pharmaceutical composition comprising a pharmaceutical product useful for preventing, reducing or controlling overweight and obesity to a patient in need thereof; (g) devices for providing (121b) supplies or support equipment for preventing, reducing or managing overweight and obesity to patients in need thereof; (h) means (152) for connecting one or more devices for measuring clinical parameters and / or anthropometric measures using an interactive user interface; (i) a database (103) for recording and storing collected clinical parameters and / or anthropometric measurements; (j) means for monitoring (112) clinical parameters and / or anthropometric data of said patient by a health care professional in the field of overweight and obesity to assess his / her health status; (k) access means for said health care professional to adjust or maintain an indication (113) for treating overweight and obesity suffered by said patient or for preventing overweight and obesity; (l) Optionally, access means for establishing communications (114) between the patient and the healthcare professional within a specified time period or upon request by the patient or the healthcare professional.

24. A method for measuring, diagnosing, treating and managing overweight and obesity using an electronic device, comprising administering a pharmaceutical product to a patient in need thereof to prevent overweight and obesity or reduce the risk thereof, characterized in that, The method comprises: (a) providing a monitoring system (200) for treatment or prevention to the patient and health care professionals, the system comprising at least: a device and interface (160a) for inputting patient identification information and / or body measurement information into a database; a device and interface (160b) for collecting and storing patient identification information and / or body measurement information in a database for incorporation into a medical record; an access device (170) for communication between the patient and health care professionals in the field of metabolic syndrome and related conditions to assess their health status; a device (170a) for indicating to the patient their health status and recording it in the medical record; a device (170b) for explaining to the patient the indications for treating the overweight and obesity or for preventing overweight and obesity; a device (121a) for providing to a patient in need thereof a pharmaceutical composition having a pharmaceutical product useful for preventing, reducing or controlling overweight and obesity; 120); means for providing (121b) supplies or support equipment for preventing, reducing or controlling overweight and obesity to patients in need thereof; means for connecting one or more devices for measuring clinical parameters and / or anthropometric indices using an interactive user interface (152); a database (103) for recording and storing collected clinical parameters and / or anthropometric indices; means for monitoring (112) the data of the clinical parameters and / or anthropometric indices of the patient by a health care professional in the field of overweight and obesity to assess their health status; access means for the health care professional to adjust or maintain the indication (113) for treating the overweight and obesity suffered by the patient or for preventing overweight and obesity; optionally, access means for establishing communication (114) between the patient and the health care professional within a specified time period or upon request of the patient or the health care professional; (b) providing the patient (100) with a pharmaceutical composition (130) having a pharmaceutical product useful for preventing, reducing or controlling overweight and obesity based on the patient's identity information and body measurement information previously stored in a database or the patient's medical record; (c) monitoring clinical parameters and / or anthropometric data of the patient by a healthcare professional (110) specializing in metabolic syndrome and related conditions using an interactive user interface connected to one or more devices for measuring clinical parameters and / or anthropometric data to assess the patient's health status.

25. A method for measuring, diagnosing, treating and managing overweight and obesity using an electronic device according to claims 16 to 21, comprising administering a pharmaceutical product to a patient (100) in need thereof to prevent or reduce the risk of overweight and obesity, wherein: The body measurements, clinical parameters and / or anthropometric indicators are selected from: weight, body mass index, % fat, height, muscle, water, visceral fat, bone, metabolism, protein, obesity level, body age, fat-free body mass, oxygenation, body oxygenation quantified in urine, vitamins and minerals, blood glucose, blood pressure, LDL cholesterol, HDL cholesterol, triglycerides, urine glucose, step counter, heart rate, fasting blood glucose, post-load blood glucose, total cholesterol, total bilirubin, alanine aminotransferase, aspartate aminotransferase and / or body temperature.

26. A method for measuring, diagnosing, treating and managing overweight and obesity using an electronic device according to claims 16 to 21, comprising administering a pharmaceutical product to a patient (100) in need thereof to prevent or reduce the risk of overweight and obesity, wherein: The measuring device (140) is selected from: a scale, an ORP, a vitamin bar, a blood glucose meter, a blood oximeter, a smart watch, a smart bracelet, smart clothing, a patch, a tattoo, an implant, a hearing aid, a helmet, an electrode, a chest strap, a pedometer, and a medical device for quantifying biochemical parameters.

27. A method for measuring, diagnosing, treating and managing overweight and obesity using an electronic device according to claims 16 to 21, comprising administering a drug to a patient (100) in need thereof to prevent overweight and obesity or reduce the risk thereof, wherein: The pharmaceutical composition (130) having a drug product useful for preventing, reducing or controlling overweight and obesity is selected from: oxidative phosphorylation chemical uncouplers, tyrosine phosphorylation inhibitor AG17, orlistat, L-carnitine, benzphetamine, phendimetrazine, diethylpropion, liraglutide, naltrexone, phentermine, topiramate, glibenclamide, metformin, acarbose, canagliflozin, dapagliflozin, saxagliptin, dulaglutide, empagliflozin, exenatide, lixisenatide, semaglutide, CBD, sibutramine, hydroxycitric acid, coenzyme q10, chromium picolinate, gamma-linolenic acid, Resveratrol, omega-3 fatty acids, antioxidants, vitamins, vitamin B, vitamin C, adrenal extract, pantothenic acid, turmeric, bayberry bark, wax bayberry, indica, tea, cocoa, emblica, holly, cascara bark, cascara bosch, acacia arabica, persimmon, blueberry leaf, grape seed, willow leaf ragweed, St. John's wort, kudzu vine, capers, gymnema, elderberry, elderberry, fructus aurantii, coffee beans, syringa chinensis, rosemary, ginger, cassia bark, kudzu vine, kidney bean, licorice root, fenugreek, yohimbe, white willow, cordyceps, ashwagandha, astragalus, ginseng, five maltose, Siberian ginseng, Asian ginseng, Indian myrrh, bitter melon, garcinia cambogia, marshmallow, bougainvillea, alfalfa, valerian, damiana, elderberry, capsicum, allium, calcium myristate, magnesium myristate, tetradecylthioacetic acid (TTA), thyroid hormone or its precursor, thyroid function enhancer, Krebs cycle metabolite, one or more endogenous uncoupling proteins such as UCP-1, UCP-2, UCP-3, PUMP (plant uncoupling mitochondrial protein) or one or more precursors, one or more agonists or enhancers thereof, leucine, valine , isoleucine, glutamine, proline, tyrosine, conjugated linoleic acid, adrenaline secretion enhancers, fatty acids or esters, beta agonists, glucagon, abutamine, vasopressin, ubiquinone, coenzyme 01, coenzyme Q2, melatonin, fatty acid esters of estrogens such as oleylestrone, glucomannan, menthol, peppermint essential oil, thyme essential oil, elemental sulfur and polyunsaturated glycol, insulin or insulin analogs and orally active hypoglycemic agents; acetohexamide, amoxicillin, chlorpropamide, glibenclamide, glibenclamide, gliclazide, glimepiride, glipizide, tolazamide and tolbutamide;2R,3R,4R,5S)-1-(2-hydroxyethyl)-2-(hydroxymethyl)piperidin-3,4,5-triol or miglitol) (1S,2S,3R,4S,5S)-5-(1,3-dihydroxypropan-2-ylamino)-1-(hydroxymethyl)-cyclohexane-1,2,3,4-tetraol), (RS)-5-[4-(2-[methyl(pyridin-2-yl)amino]ethoxy)benzyl]thiazolidine-2,4-dione, (R (S)-5-(4-[2-(5-ethylpyridin-2-yl)ethoxy]benzyl)thiazolidine-2,4-dione, 5-[(4-[2-([6-(4-methoxyphenoxy)pyrimidin-4-yl]-methylamino)ethoxy]phenyl-)methyl]-1,3-thiazolidine-2,4-dione, (RS)-5-(4-[(6-hydroxy-2,5,7,8-tetramethylchroman-2-yl)methoxy]benzyl)thiazolidine-2,4-dione;(S)-(+)-2-ethoxy-4-[2-(3-methyl-1-[2-(piperidin-1-yl)phenyl]butylamino)-2-oxyylideneethyl]benzoic acid, 3-phenyl-2-[(4-propan-2-ylcyclohexanecarbonyl)amino]propionic acid, (2S)-2-benzyl-4-[(3aR,7aS)-octahydro-2H-isoindol-2-yl]-4-oxyylidenebutanoic acid, L-ornithine, L-tyrosine, L-tryptophan, L-phenylalanine, conjugated linoleic acid, gamma-linolenic acid, chromium picolinate, Glucose tolerance factor, vanadyl sulfate, gymnema, bromelain, pancreatin, papain, coenzyme Q10, curcumin, berberis, bearberry, silymarin, angustifolia, choline, inositol, human growth hormone, DHEA (dehydroepiandrosterone), caffeine, xanthenes (such as fucoxanthin), kola nut, plantain, mate, guarana, ginseng, medium chain triglycerides, hydroxycitric acid (HCA), kelp, lecithin, dihydroxyacetone, pyruvate, creatine, iodine, niacin, fucus, white bean extract, glucomannan, Chitosan, resveratrol, resveratrol derivatives, vitamin D, hCG, capsaicin, chia, apple cider vinegar, coconut oil, bitter orange, vitamin B, fluoxetine, chitosan, chromium picolinate, conjugated linoleic acid (CLA), glucomannan, green tea extract, green coffee extract, guar gum, Hoodia cactus, 7-keto-DHEA, DHEA, ephedra, bitter orange, turmeric, ginger, root powder, apple cider vinegar, calcium, hesperidin, gynostemma pentaphyllum total saponin, extract flaxseed oil, orange peel powder, thiamine, ashwagandha extract, coffee extract Extract, L-theanine, choline bitartrate, red mango extract, white kidney bean extract, coffee robusta extract, acetyl-L carnitine, garcinia, turmeric extract, coconut oil, forskolin extract, black pepper extract paroxetine, citalopram, bupropion, topiramate, icopipan, naltrexone, peptide YY3-36, leptin, amphetamine, amphetamine, phentermine, mazindol phendimetrazine, fenfluramine, dexfenfluramine, pharmaceutically acceptable salts and derivatives thereof, and mixtures thereof. ; 28. The method for measuring, diagnosing, treating and managing overweight and obesity using an electronic device according to claim 27, comprising administering a pharmaceutical product to a patient (100) in need thereof to prevent or reduce the risk of overweight and obesity, wherein: The oxidative phosphorylation chemical uncoupler is selected from: 4,4-bis-(4-hydroxy-3-nitrophenyl)-pentanoic acid, 4-methoxy-2-nitrophenol, 4-hydroxy-3-nitroacetophenone, 7-hydroxy-4-methyl-8-nitro-chromen-2-one, 3-tert-butyl-5-chloro-N-(2-chloro-4-nitrophenyl)-2-hydroxy-6-methyl-benzamide, N-1-[4-cyano-3-(trifluoromethyl)phenyl]-3,5-bis(trifluoromethyl)benzamide, N -(4-cyanophenyl)benzamide, 2′-chloro-1-hydroxy-4′-nitro-2-naphthoic acid anilide, N-(2-chloro-4-bromophenyl)-5-bromosalicylic acid anilide, N-(2-chloro-4-nitrophenyl)-3-tert-butyl-6-methylsalicylic acid anilide, (3,5-di-tert-butyl-4-hydroxybenzyl)triphenylphosphonium bromide, (3,5-di-tert-butyl-4-hydroxybenzyl)tricyclohexylphosphonium bromide, (3,5-di-tert-butyl-4-hydroxybenzyl)tributylphosphonium bromide, 3,5-di-tert-butyl-4-hydroxybenzyl) trioctylphosphonium bromide, 2-cyano-3-(3,5-di-tert-butyl-4-hydroxyphenyl)-acrylate, 2-(3,5-di-tert-butyl-4-hydroxy-benzylidene)-malonic acid diethyl ester, 2-amino-S-[(3,5-di-tert-butyl-4-hydroxybenzylidene)-amino]-but-2-enediconitrile, 2-(3,5-di-tert-butyl-4-hydroxy-benzylidene)-indan-1,3-dione, 2-[[2-(4- chlorophenyl)-1H-indol-3-yl]methylene]malononitrile, 2-(4-chlorophenyl)-indole, N-(2,4,5-trichlorophenyl) salicylanilide, 2,3-dimethyl-5-cyano-7-ethylindole, 4-bromo-2-(4-chlorophenyl)-5-trifluoromethyl-1H-pyrrole-3-carbonitrile, N-(3-cyano-4-phenylthio-phenyl)-3-trifluoromethyl-benzamide, 2,4-dinitrophenol, carbonyl cyanide p-trifluoromethoxyphenylhydrazone, 2-(5,7-dimethyl-1H-indol-3-ylmethylene)-malononitrile, 2-(5-bromo-1H-indol-3-ylmethylene)-malononitrile, 2-((5-chloro-1H-indol-3-yl)methylene)malononitrile, 2-((5-methyl-1H-indol-3-yl)methylene)malononitrile, 2-((5-methyl-1H-indol-3-yl)methylene)malononitrile, 2-((5-methyl-1H-indol-3-yl)methylene)malononitrile, 2-(2-phenyl-3-indolylmethylene)-malononitrile, 2-(2-chloro-1H-indol-3-ylmethylene)-malononitrile, 2-(5-nitro-1H-indol-3-ylmethylene)-malononitrile, 2-(2-methyl-5-nitro-1H-indol-3-ylmethylene)-malononitrile, 3-bromo-5-tert-butyl Benzamide, 3-tert-butyl-N-(2-chloro-4-nitrophenyl)-6-hydroxy-2-methyl-benzamide, N-(2-chloro-4-nitrophenyl)-2-hydroxy-3-isopropyl-benzamide, N-(2-chloro-4-nitrophenyl)-2-hydroxy-3-isopropyl-6-methyl-benzamide, 3,5-di-tert-butyl-N-(2-chloro-4-nitrophenyl)-2-hydroxy-benzamide, 3-bromo-N-(2-chloro-4-nitrophenyl)-6-hydroxy-5-isopropyl-2-methyl-benzamide, 3-tert-butyl-5-chloro-N-(4-chloro-3-trifluoromethyl-phenyl)-2-hydroxy-6-methyl-benzamide, 3-tert-butyl-5-chloro-N-(4-cyano-3-trifluoromethyl-phenyl)-2-hydroxy-6-methyl-benzamide 2-Hydroxy-biphenyl-3-carboxylic acid (2-chloro-4-nitro-phenyl)-amide, 3-tert-butyl-N-(2-chloro-4-nitro-phenyl)-2-hydroxy-5-methyl-benzamide, N-(2-chloro-4-nitro-phenyl)-2-hydroxy-6-isopropyl-3-methyl-benzamide, N-(3,5-bis-trifluoromethyl-phenyl)-3-tert-butyl-5-chloro-2-hydroxy-6-methyl-benzamide, 3-tert-butyl-5-chloro-N-(2-fluoro-5-trifluoromethyl-phenyl)-2-hydroxy-6-methyl-benzamide, 3-tert-butyl-5-chloro-2-hydroxy-6-methyl-N-(4-nitro-3 -trifluoromethyl-phenyl)-benzamide, 3-tert-butyl-5-chloro-2-hydroxy-6-methyl-N-(4-nitro-2-trifluoromethyl-phenyl)-benzamide, 3-bromo-5-tert-butyl-N-(2-chloro-4-cyano-phenyl)-6-hydroxy-2-methyl-benzamide, 3-bromo-5-tert-butyl-N-(2-chloro-5-trifluoromethyl-phenyl)-6-hydroxy-2-methyl-benzamide, 3-bromo-5-tert-butyl-N-(2,4-dichloro-phenyl)-6-hydroxy-2-methyl-benzamide, 3-bromo-5-tert-butyl-N-(2,4-dichloro-6-nitro-phenyl)-6-hydroxy-2-methyl-benzamide,6-dichloro-4-nitro-phenyl)-6-hydroxy-2-methyl-benzamide, 3-bromo-5-tert-butyl-N-{5-chloro-4-[(4-chloro-phenyl)-cyano-methyl]-2-methyl-phenyl}-6-hydroxy-2-methyl-benzamide, 3-bromo-6-hydroxy-5-isopropyl-2-methyl-N-(4-nitro-2-trifluoromethyl-phenyl)-benzamide, 3-bromo-5-tert-butyl-6-hydroxy-2-methyl-N-(4-nitro-2-trifluoromethyl-phenyl)-benzamide, 3-tert-butyl-2-hydroxy-6-methyl-N-(4-nitro-2-trifluoromethyl-phenyl)-benzamide, 3-bromo-N-(2-bromo-3,5-bis-trifluoromethyl)-benzamide methyl-phenyl)-5-tert-butyl-6-hydroxy-2-methylbenzamide, N-(2,5-bis-trifluoromethyl-phenyl)-3-bromo-5-tert-butyl-6-hydroxy-2-methyl-benzamide, 3-bromo-5-tert-butyl-N-(2,4-dichloro-6-trifluoromethyl-phenyl)-6-hydroxy-2-methylbenzamide, 3-bromo-5-tert-butyl-6-hydroxy-N-(4-isopropyl-2-trifluoromethyl-phenyl)-2-methyl-benzamide, N-(3,5-bis-trifluoromethyl-phenyl)-3-fluoro-5-trifluoromethyl-benzamide, 3-fluoro-N-(4-nitro-3-trifluoromethyl-phenyl)-5-trifluoromethyl-benzamide, N-(3,5-bis-trifluoromethyl-phenyl)-3-fluoro-5-trifluoromethyl-benzamide bis(trifluoromethyl-phenyl)-3-fluoro-4-trifluoromethyl-benzamide, 4-fluoro-N-(4-nitro-3-trifluoromethyl-phenyl)-3-trifluoromethyl-benzamide, 3-(3,5-di-tert-butyl-4-hydroxy-phenyl-2-(2,2-dimethyl-propionyl)-acrylonitrile, 2-acetyl-3-(3,5-di-tert-butyl-4-hydroxy-phenyl)-ethyl acrylate, 2-(3,5-dimethyl-4-hydroxy-benzylidene)-malononitrile, 2-(3,5-dimethyl-4-hydroxy-benzylidene)-malononitrile, 2,6-di-tert-butyl-4-nitrophenol, 2-tert-butyl-4,6-dinitrophenol, 3-(3,5-di-tert-butyl-4-hydroxy 3-(3,5-di-tert-butyl-4-hydroxy-phenyl)-2-pyridin-2-yl-acrylonitrile, 2-[1-(3,5-di-tert-butyl-4-hydroxy-phenyl)-ethylidene]-malononitrile, 3-(3,5-di-tert-butyl-4-hydroxybenzylidene)-2-(diethylphosphonate)-acrylonitrile, 3-(3,5-di-tert-butyl-4-hydroxy-phenyl)-2-(4-nitro-phenyl)-acrylonitrile, 3-(3,5-di-tert-butyl-4-hydroxy-phenyl)-2-pyridin-4-yl-acrylonitrile, 2-(3,5-bis-trifluoromethyl-phenyl)-3-(3,5-di-tert-butyl-4-hydroxy-phenyl)-acrylonitrile, 3-(3,5-di-tert-butyl-4-hydroxy-phenyl)-2-(4-trifluoromethoxy-benzene, 2-cyano-3-(3,5-di-tert-butyl-4-hydroxy-phenyl)-but-2-enoic acid ethyl ester, N-(4-chloro-phenyl)-2-cyano-3-(3,5-di-tert-butyl-4-hydroxy-phenyl)-acrylamide, (E)-3-(3,5-di-tert-butyl- 4-hydroxy-phenyl)-2-methanesulfonyl-acrylonitrile, (E)-2-(4-chloro-benzenesulfonyl)-3-(3,5-di-tert-butyl-4-hydroxy-phenyl)-acrylonitrile, (E)-3-(3,5-di-tert-butyl-4-hydroxyphenyl)-2-(4-fluoro-benzenesulfonyl)-acrylonitrile, (E)-2-benzenesulfonyl-3-(3,5-di-tert-butyl-4-hydroxy-phenyl)-acrylonitrile, (E)-3-(3,5-di-tert-butyl-4-hydroxy-phenyl)-2-(propane-2-sulfonyl)-acrylonitrile, 3-(3,5-di-tert-butyl-4-hydroxy-phenyl)-2-(2,5-dichloro-benzenesulfonyl)-acrylonitrile, 3-(3,5-di-tert-butyl-4-hydroxy-phenyl)-2-(2,4-dichloro-benzenesulfonyl)-acrylonitrile, 3-(3,5-di-tert-butyl-4-hydroxy-phenyl)-2-(hexane-1-sulfonyl)-acrylonitrile, 2-(4-bromo-benzenesulfonyl)-3-(3,5 -di-tert-butyl-4-hydroxy-phenyl)-acrylonitrile, 2-(3-bromo-benzenesulfonyl)-3-(3,5-di-tert-butyl-4-hydroxy-phenyl)-acrylonitrile, 5-bromo-3-tert-butyl-N-(2-chloro-4-cyanophenyl)-2-hydroxybenzamide, 5-bromo-3-tert-butyl-N-(4-cyanophenyl)-2-hydroxybenzamide, 3-bromo-5-tert-butyl-6-hydroxy-2-methyl-N-(2-trifluoromethylphenyl)benzamide, 2-(2-bromo-1H-indol-3-ylmethylene)malononitrile, 2-(7-bromo-2-methyl-1H-indol-3-ylmethylene)malononitrile, 2-(5-bromo-2-methyl-1H-indol-3-ylmethylene)malononitrile, pharmaceutically acceptable salts thereof and derivatives thereof and mixtures thereof.

29. A method for measuring, diagnosing, treating and managing overweight and obesity using an electronic device according to claims 16 to 21, comprising administering a pharmaceutical product to a patient (100) in need thereof to prevent or reduce the risk of overweight and obesity, wherein: The pharmaceutical composition (130) with a drug product includes a drug product for preventing, alleviating or controlling hypertension, selected from: alprenolol, atenolol, timolol, pindolol, propranolol and metoprolol, ACE (angiotensin converting enzyme) inhibitors such as benazepril, captopril, enalapril, fosinopril, lisinopril, quinapril and ramipril, calcium channel blockers such as nifedipine, felodipine, nicardipine, isradipine, nimodipine, diltiazem and verapamil, and [α]-blockers such as doxazosin, urapidil, prazosin and terazosin, pharmaceutically acceptable salts and derivatives thereof and mixtures thereof.

30. A method for measuring, diagnosing, treating and managing overweight and obesity using an electronic device according to claims 16 to 21, comprising administering a pharmaceutical product to a patient (100) in need thereof to prevent or reduce the risk of metabolic syndrome and related conditions, wherein: The pharmaceutical composition (130) with a drug comprises a drug product for preventing, alleviating or controlling hyperglycemia (type I diabetes or type II diabetes) selected from: oxidative phosphorylation chemical uncouplers or derivatives thereof, agents acting on the ATP-dependent potassium channels of pancreatic [β] cells, biguanides, imidazolines, [α]-glucosidase inhibitors, meglitinides, oxadiazolidinediones, thiazolidinediones, insulin sensitizers, sulfonylureas, potassium channel blockers such as nateglinide or BTS-67582, glucagon antagonists, DPP-IV (dipeptidyl peptidase-IV) inhibitors, PTPase (protein tyrosine phosphatase) inhibitors, glucose kinase kinase inhibitors active agents, inhibitors of liver enzymes involved in stimulating gluconeogenesis and / or glycogenolysis, regulators of glucose uptake, GSK-3 (glycogen synthase kinase-3) inhibitors, compounds that alter lipid metabolism such as anti-hyperlipidemic and hypolipidemic drugs, compounds that reduce food intake, and PPAR agonists; for example: tyrosine phosphorylation inhibitor AG17, tyrosine phosphorylation inhibitor A9, insulin and insulin analogs, tolbutamide, chlorpropamide, tolazamide, glibenclamide, glipizide, glimepiride, gliclazide or glyburide, metformin, repaglinide or senaglinide / nateglinide, troglitazone, pioglitazone, rosiglitazone, isoglitazone, darglitazone, englitazone, GI 262570, YM-440, MCC-555, JTT-501, AR-H039242, KRP-297, GW-409544, CRE-16336, AR-H, voglibose, emiglitate, miglitol or acarbose, tolbutamide, glibenclamide, glipizide, gliclazide, BTS-67582 or repaglinide, nateglinide, colestiamide, colestipol, clofibrate, gemfibrozil, lovastatin, pravastatin, simvastatin, pharmaceutically acceptable salts and derivatives thereof and mixtures thereof.